


# CURRENT DEVELOPMENTS IN THE DETECTION AND CONTROL OF MULTI DRUG RESISTANCE



Editors:

**Sanket Kaushik**  
**Nagendra Singh**

**Bentham Books**

# **Current Developments in the Detection and Control of Multi Drug Resistance**

Edited by

**Sanket Kaushik**

*Amity Institute of Biotechnology*

*Amity University Rajasthan*

*Jaipur- 303002,*

*India*

&

**Nagendra Singh**

*School of Biotechnology*

*Gautam Buddha University*

*Greater Noida- 201308,*

*India*

## **Current Developments in the Detection and Control of Multi Drug Resistance**

Editors: Sanket Kaushik and Nagendra Singh

ISBN (Online): 978-981-5049-87-9

ISBN (Print): 978-981-5049-88-6

ISBN (Paperback): 978-981-5049-89-3

© 2022, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

First published in 2022.

## **BENTHAM SCIENCE PUBLISHERS LTD.**

### **End User License Agreement (for non-institutional, personal use)**

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: [permission@benthamscience.net](mailto:permission@benthamscience.net).

### **Usage Rules:**

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

### ***Disclaimer:***

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

### ***Limitation of Liability:***

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

### **General:**

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the



need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

**Bentham Science Publishers Pte. Ltd.**

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: [subscriptions@benthamscience.net](mailto:subscriptions@benthamscience.net)



## CONTENTS

<b>PREFACE</b> .....	i
<b>LIST OF CONTRIBUTORS</b> .....	ii
<b>CHAPTER 1 INTRODUCTION</b> .....	1
<i>Sanket Kaushik and Nagendra Singh</i>	
<b>CONSENT FOR PUBLICATION</b> .....	3
<b>CONFLICT OF INTEREST</b> .....	3
<b>ACKNOWLEDGEMENTS</b> .....	3
<b>REFERENCES</b> .....	3
<b>CHAPTER 2 DEVELOPMENT OF DRUG RESISTANCE</b> .....	6
<i>Divyapriya Karthikeyan, Mukesh Kumar, Jyoti Yadav, Amit Alok, Kishore K. R. Tetala and Sanjit Kumar</i>	
<b>INTRODUCTION</b> .....	6
<b>CONCLUSION</b> .....	10
<b>CONSENT FOR PUBLICATION</b> .....	10
<b>CONFLICT OF INTEREST</b> .....	10
<b>ACKNOWLEDGEMENTS</b> .....	10
<b>REFERENCES</b> .....	10
<b>CHAPTER 3 CURRENT CHALLENGES IN TREATING MDR</b> .....	13
<i>Vaishali Gurjar, Ayushi Khurana, Gunjan Shaily, Sanket Kaushik and Nagendra Singh</i>	
<b>INTRODUCTION</b> .....	13
Natural/Intrinsic Resistance .....	14
Acquired Resistance .....	14
<b>MECHANISMS OF MDR DEVELOPMENT</b> .....	14
Alteration of the Target Protein by Mutation .....	15
Modifications of the Drug .....	15
Decreased Antibiotic Penetration and Efflux .....	16
Gene Acquisition from other Species for Less Susceptible Target Proteins .....	17
Target Bypassing .....	17
<b>PREVENTING MDR</b> .....	18
MDR Preventive Measures .....	18
<i>Political Commitment</i> .....	18
<i>Case Finding</i> .....	19
<i>Standardized and Supervised Drug Treatment Course</i> .....	19
<i>Surveillance System</i> .....	19
<i>Development of Novel Drugs</i> .....	19
<b>STRATEGIES TO COMBAT MDR</b> .....	19
Antimicrobial Peptides (AMPs) .....	19
Anti-virulence Compounds .....	20
Phage Therapy Alone or in Combinations with Antibiotics .....	20
New Molecules .....	21
Drug Repurposing and Repositioning .....	21
Hand Hygiene .....	22
Patient Placement and Priority for Isolation .....	22
Personal Protective Equipment (PPE) .....	23
Cleaning of the Environment and Patient Care Equipment .....	23
Patient Movement and Transfer .....	24

Education of Patients, Staff and Visitors .....	24
<b>CHALLENGES</b> .....	24
Challenges in Diagnosis .....	25
Disease Transmission .....	25
Treatment of Latent Infection .....	26
<b>WHO'S RESPONSE TO MDR</b> .....	26
<b>CONCLUSION</b> .....	26
<b>CONSENT FOR PUBLICATION</b> .....	27
<b>CONFLICT OF INTEREST</b> .....	27
<b>ACKNOWLEDGEMENTS</b> .....	27
<b>LIST OF ABBREVIATIONS</b> .....	28
<b>REFERENCES</b> .....	28
<b>CHAPTER 4 METHODS OF DETECTION OF MDR</b> .....	33
<i>Monish Bisen, Anupam Jyoti and Juhi Saxena</i>	
<b>INTRODUCTION</b> .....	33
<b>TECHNIQUES TO DETECT MDR</b> .....	35
Culture .....	35
<i>Liquid Culture-based Methods</i> .....	36
<i>Solid-culture Methods</i> .....	36
Polymerase Chain Reaction .....	37
<i>Advantages</i> .....	37
<i>Disadvantages</i> .....	37
Lateral Flow Immunoassay .....	37
<i>Advantages</i> .....	38
<i>Disadvantages</i> .....	38
DNA Microarray .....	38
<i>Advantages</i> .....	38
<i>Disadvantages</i> .....	39
Whole Genome Sequencing .....	39
<i>Advantages</i> .....	39
<i>Disadvantages</i> .....	39
<b>CONCLUSIONS</b> .....	39
<b>CONSENT FOR PUBLICATION</b> .....	40
<b>CONFLICT OF INTEREST</b> .....	40
<b>ACKNOWLEDGEMENTS</b> .....	40
<b>REFERENCES</b> .....	40
<b>CHAPTER 5 MOLECULAR PROBES AS DIAGNOSTIC TOOLS</b> .....	43
<i>Anurag Jyoti and Rajesh Singh Tomar</i>	
<b>INTRODUCTION</b> .....	43
<b>MOLECULAR DIAGNOSTICS FOR DETECTION OF DRUG-RESISTANT</b>	
<b>PATHOGENS</b> .....	44
Polymerase Chain Reactions (PCR) .....	45
Real Time Polymerase Chain Reactions (PCR) .....	46
Detection Chemistries .....	46
<i>Nucleic Acid Dye: SYBR Green I</i> .....	46
<i>Sequence-specific Probe</i> .....	47
<b>CONCLUSION</b> .....	47
<b>CONSENT FOR PUBLICATION</b> .....	48
<b>CONFLICT OF INTEREST</b> .....	48
<b>ACKNOWLEDGEMENTS</b> .....	48

<b>REFERENCES</b> .....	48
<b>CHAPTER 6 REAL-TIME PCR HIGH-RESOLUTION MELTING ANALYSIS</b> .....	50
<i>Ena Gupta, Sanket Kaushik, Vijay Kumar Srivastava, Juhi Saxena and Anupam Jyoti</i>	
<b>INTRODUCTION</b> .....	50
<b>PRINCIPLE OF THE MELTING PROFILE</b> .....	52
<b>INTERCALATING DYES</b> .....	53
Non-saturating Dyes .....	53
Saturating Dyes .....	54
Release-on-demand Dyes .....	54
<b>WORKING OF PCR-HRM</b> .....	54
Analysis of Data .....	55
Factors Affecting HRM .....	55
<b>APPLICATIONS</b> .....	57
Identification of Microbial Species .....	57
Mutation Detection .....	58
Microbial Genotyping within Species .....	58
Identification of Genotypic Variants Leading to Antimicrobial Resistance .....	58
Identification of Human Genetic Variants of Importance to Susceptibility to or Treatment of Infectious Diseases .....	59
Alternative for Gel Electrophoresis .....	59
<b>CONCLUSION</b> .....	60
<b>CONSENT FOR PUBLICATION</b> .....	60
<b>CONFLICT OF INTEREST</b> .....	60
<b>ACKNOWLEDGEMENTS</b> .....	60
<b>REFERENCES</b> .....	61
<b>CHAPTER 7 CURRENT THERAPEUTIC OPTIONS AND CHALLENGES FOR MDR</b> .....	66
<i>Aakanksha Kalra, Sakshi Piplani and Ravi Ranjan Kumar Niraj</i>	
<b>INTRODUCTION</b> .....	66
<b>TRADITIONAL METHODS USED FOR TREATMENT OF MDR</b> .....	67
Major Antibiotics used for Treatment of MDR Bacteria .....	68
<i>Carbapenems</i> .....	69
<i>Polymyxins</i> .....	69
<i>Aminoglycosides</i> .....	70
<i>Oxazolidinone</i> .....	70
<i>Glycylcycline</i> .....	70
Synergistic Approach by Combination of Antibiotics .....	71
Bioenhancers .....	72
<b>CURRENT TREATMENT METHODS USED FOR TREATING PATIENTS WITH MDR BACTERIAL INFECTIONS</b> .....	73
Use of Anti-microbial Peptides as Therapeutic Agent .....	73
Anti-Virulence Compounds .....	73
Drug Repurposing .....	74
Phage Therapy for Treatment of MDR Bacteria .....	75
<b>CONCLUSION</b> .....	76
<b>CONSENT FOR PUBLICATION</b> .....	76
<b>CONFLICT OF INTEREST</b> .....	76
<b>ACKNOWLEDGEMENTS</b> .....	76
<b>REFERENCES</b> .....	76

<b>CHAPTER 8 PHYTOMEDICINES FOR BACTERIAL INFECTIONS</b> .....	79
<i>Vijay Pal, Ravneet Chug, Kumar Sambhav Verma, Priyal Sharma and Vinod Singh Gour</i>	
<b>INTRODUCTION</b> .....	79
<b>TREES AND SEED OIL</b> .....	81
<b>SEED OIL CHEMICAL COMPOSITION</b> .....	81
<b>ANTIMICROBIAL ACTIVITIES IN SEED OIL</b> .....	83
<b>CONCLUSION AND FUTURE PROSPECTS</b> .....	85
<b>CONSENT FOR PUBLICATION</b> .....	85
<b>CONFLICT OF INTEREST</b> .....	85
<b>ACKNOWLEDGEMENTS</b> .....	85
<b>REFERENCES</b> .....	86
<b>CHAPTER 9 MOLECULAR MECHANISMS OF ANTIMICROBIAL RESISTANCE AND NEW TARGETS TO ADDRESS CURRENT DRUG RESISTANCE</b> .....	89
<i>Divyapriya Karthikeyan, Sudhir Kumar Pal, Mukesh Kumar, Kali Kishore Reddy Tetala, Punit Kaur and Sanjit Kumar</i>	
<b>INTRODUCTION</b> .....	89
<b>ANTIQUITY OF ANTIBIOTIC EXPLORATION AND CONCOMITANT PROGRESS OF ANTIBIOTIC RESISTANCE</b> .....	90
<b>THE SCENARIO OF DRUG RESISTANCE: GLOBAL AND INDIAN PERSPECTIVE</b> ....	95
<b>SUPERBUGS AND DRUG RESISTANCE</b> .....	98
<b>MOLECULAR MECHANISMS OF THE RESISTANCE</b> .....	100
Decreased Antibiotics Permeability .....	100
Depravity of Antibacterials by Bacterial Enzymes .....	101
Enhanced Antimicrobials Efflux .....	101
Alternative Pathway Usage by Bacteria .....	101
Drug Target Modification .....	101
<b>OTHER FACTORS CAUSING ANTIMICROBIAL DRUG RESISTANCE</b> .....	101
Self-medication (Drug Abuse) .....	101
Evolution and Transmission of Resistance Genes .....	102
Travel, Migration, and Trade .....	103
Population Mediated Pollution .....	103
Climatic Change .....	103
Antibiotic Use in Agriculture and Animals .....	104
<b>SURVEILLANCE MECHANISM FOR ANTIMICROBIAL RESISTANCE</b> .....	104
<b>SUBDUE ANTIMICROBIAL RESISTANCE</b> .....	107
New Targets to Address Current Drug Resistance .....	107
<i>Raetz Pathway</i> .....	107
<i>Other New Antimicrobial Targets</i> .....	109
Implementation of Antimicrobial Stewardship Programs .....	109
Non-Prescription Antibiotics .....	110
Reducing Antibiotic Use in Agriculture and Animals .....	110
Vaccination .....	111
Clean and Hygiene .....	112
Antibiotic Channel Revitalization .....	112
<b>NATIONAL POLICIES TO CONSERVE ANTIBIOTIC EFFECTIVENESS</b> .....	112
Recommendations from Infectious Diseases Society of America's (IDSA) .....	113
<b>CONCLUSION</b> .....	113
<b>CONSENT FOR PUBLICATION</b> .....	114
<b>CONFLICT OF INTEREST</b> .....	114

ACKNOWLEDGEMENTS .....	114
REFERENCES .....	114
<b>CHAPTER 10 DRUG DISCOVERY FOR MDR</b> .....	126
<i>Jyoti Yadav, Nagendra Singh, Anupam Jyoti, Vijay Kumar Srivastava, Vinay Sharma and Sanket Kaushik</i>	
INTRODUCTION .....	126
EMERGENCE OF MULTIDRUG RESISTANCE IN BACTERIA .....	127
ROLE OF STRUCTURAL BIOLOGY IN DRUG DISCOVERY .....	128
X-RAY CRYSTALLOGRAPHY AND COMPUTATIONAL METHODS FOR LIGAND SCREENING IN DRUG DISCOVERY .....	131
CHALLENGES AND STRATEGIES FOR TREATMENT OF MULTI DRUG RESISTANT INFECTIONS .....	132
Antimicrobial Peptides (AMPs) .....	133
Phage Therapies .....	134
Quorum Sensing (QS) and Efflux Pump Inhibitors .....	134
CONCLUSION .....	134
CONSENT FOR PUBLICATION .....	135
CONFLICT OF INTEREST .....	135
ACKNOWLEDGEMENTS .....	135
REFERENCES .....	135
<b>CHAPTER 11 RECENT DEVELOPMENTS TO FIGHT MULTIDRUG RESISTANCE (MDR) IN PROTOZOA</b> .....	141
<i>Mrinalini Roy, Sanket Kaushik, Anupam Jyoti and Vijay Kumar Srivastava</i>	
INTRODUCTION .....	142
NEWLY SYNTHESIZED ORGANIC COMPOUNDS .....	142
DRUG DISCOVERY FROM NATURAL COMPOUND LIBRARIES .....	145
Protease Inhibitors .....	145
Topoisomerase Inhibitors .....	146
Antimicrobial Peptides .....	146
Other Natural Protozoa Inhibitors .....	147
THE DRUG REPURPOSING APPROACH .....	147
THERAPEUTIC APPLICATIONS OF RNA INTERFERENCE (RNAI) .....	148
COMPUTATIONAL-BASED STRATEGIES FOR DRUG DISCOVERY .....	149
CONCLUDING REMARKS .....	150
FUTURE PERSPECTIVE .....	151
CONSENT FOR PUBLICATION .....	151
CONFLICT OF INTEREST .....	152
ACKNOWLEDGEMENTS .....	152
REFERENCES .....	152
SUBJECT INDEX .....	379

## PREFACE

The ability of different species of bacteria to resist the antimicrobial agent has become a global problem. Despite the development of so many antibiotic molecules during the last fifty years, increasing antibiotic resistance worldwide may lead to therapeutic dead-end. The disease burden from multidrug-resistant strains of organisms causing AIDS, tuberculosis, gonorrhoea, malaria, influenza, pneumonia, and diarrhoea is being felt in both the developed and the developing countries alike. This book summarizes the emerging trends in the field of antibiotic resistance of various MDR bacterial species.

Current strategies of detection and control of multidrug resistant bacteria provides the clear and recent information regarding strategies involved in diagnosis and treatment of MDR bacteria. Over the past decades, due to the exponential rise in the infections caused by MDR bacteria, it is necessary to elucidate the basic mechanism of antibiotic resistance to find out the effective methods for treatment and control. Primary goal of this book is to elaborate and enhance the theoretical knowledge of bacterial pathogenesis, diagnosis and treatment. It concentrates on further elaboration of current strategies of detection and control of MDR bacteria, Quantification of pathogenic bacteria, High Resolution Melting Analysis techniques, Biosynthesis pathways and Rational structure based drug design for MDR infections.

We have attempted to provide large amount of information in each chapter supplemented with in- depth knowledge of current strategies of detection and control of MDR bacteria. This book enhances the knowledge of Microbiology, Biotechnology and Life sciences in field area of MDR pathogenesis and control. The idea to encompass knowledge spanning from what is known to what is unknown in the writings from the experts in the field will result in a rigorous effort to justify the various topics.

We strongly believe that this book will be reader's delight providing comprehensive understanding of diagnosis and treatment of MDR bacteria. It will be an ideal resource for student's better understanding of MDR bacteria biology and useful for biomedical students, cellular and molecular biologists. I hope you will find this book interesting and relevant.

**Sanket Kaushik**

Amity Institute of Biotechnology  
Amity University Rajasthan  
Jaipur- 303002, India

&

**Nagendra Singh**

School of Biotechnology  
Gautam Buddha University  
Greater Noida- 201308, India



## List of Contributors

<b>Aakanksha Kalra</b>	Dr B. Lal Institute of Biotechnology, Jaipur, 302017, India
<b>Amit Alok</b>	Division of Radiation Biodosimetry, Institute of Nuclear Medicine and Allied Sciences, Timarpur, Delhi, 110054, India
<b>Anupam Jyoti</b>	Department of Biotechnology, University Institute of aBiotechnology, Chandigarh University, Mohali, Punjab, 140413, India
<b>Anurag Jyoti</b>	Amity University Madhya Pradesh, Maharajpura Dang, Gwalior-474005, M.P., India
<b>Ayushi Khurana</b>	School of Biotechnology, Gautam Buddha University, Greater Noida, India
<b>Divyapriya Karthikeyan</b>	Centre for Bioseparation Technology (CBST), Vellore Institute of Technology (VIT), Vellore, Tamil Nadu, India
<b>Ena Gupta</b>	Amity Institute of Biotechnology, Amity University Rajasthan, Amity Education Valley, Kant Kalwar, NH-11C, Jaipur-Delhi Highway, Jaipur, India
<b>Gunjan Shaily</b>	School of Biotechnology, Gautam Buddha University, Greater Noida, India
<b>Juhi Saxena</b>	Department of Biotechnology, University Institute of aBiotechnology, Chandigarh University, Mohali, Punjab, 140413, India
<b>Jyoti Yadav</b>	Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur-303002, India
<b>Kali Kishore Reddy Tetala</b>	Centre for Bio Separation Technology (CBST), Vellore Institute of Technology, Vellore, Tamil Nadu, India
<b>Kishore K.R. Tetala</b>	Centre for Bioseparation Technology (CBST), Vellore Institute of Technology (VIT), Vellore, 632014, Tamil Nadu, India
<b>Kumar Sambhav Verma</b>	Amity Institute of Biotechnology, Amity University Rajasthan, NH 11 C Kant Kalwar, Jaipur, India
<b>Monish Bisen</b>	Faculty of Applied Sciences and Biotechnology, Shoolini University of Biotechnology and Management Sciences, Bajhol, Solan, Himachal Pradesh 173229, India
<b>Mrinalini Roy</b>	Amity Institute of Biotechnology, Amity University Rajasthan, Kant Kalwar, NH-11C, Jaipur-Delhi Highway, Jaipur, India
<b>Mukesh Kumar</b>	Department of Biophysics, All India Institute of Medical Sciences, New Delhi, New Delhi, India
<b>Nagendra Singh</b>	School of Biotechnology, Gautam Buddha University, Greater Noida- 201308, India
<b>Priyal Sharma</b>	Amity Institute of Biotechnology, Amity University Rajasthan, NH 11 C Kant Kalwar, Jaipur, India
<b>Punit Kaur</b>	Department of Biophysics, All India Institute of Medical Sciences, New-Delhi, India
<b>Rajesh Singh Tomar</b>	Amity Institute of Biotechnology, Amity University Madhya Pradesh, Maharajpura Dang, Gwalior-474005, M.P., India

<b>Ravi Ranjan Kumar Niraj</b>	Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur, 303002, India
<b>Ravneet Chug</b>	Amity Institute of Biotechnology, Amity University Rajasthan, NH 11 C Kant Kalwar, Jaipur, India
<b>Sakshi Piplani</b>	Vaxine Pty Ltd, Warradale, Australia; College of Medicine and Public Health, Flinders University, Adelaide, Australia
<b>Sanjit Kumar</b>	Centre for Bioseparation Technology (CBST), Vellore Institute of Technology (VIT), Vellore, Tamil Nadu, India
<b>Sanket Kaushik</b>	Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur- 303002, India
<b>Sudhir Kumar Pal</b>	Centre for Bio Separation Technology (CBST), Vellore Institute of Technology, Vellore, Tamil Nadu, India
<b>Vaishali Gurjar</b>	School of Biotechnology, Gautam Buddha University, Greater Noida, India
<b>Vijay Kumar Srivastava</b>	Amity Institute of Biotechnology, Amity University Rajasthan, Amity Education Valley, Kant Kalwar, NH-11C, Jaipur-Delhi Highway, Jaipur, India
<b>Vijay Pal</b>	Amity Institute of Biotechnology, Amity University Rajasthan, NH 11 C Kant Kalwar, Jaipur, India
<b>Vinay Sharma</b>	Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur-303002, India
<b>Vinod Singh Gour</b>	Amity Institute of Biotechnology, Amity University Rajasthan, NH 11 C Kant Kalwar, Jaipur, India

---

**CHAPTER 1**

---

**Introduction****Sanket Kaushik<sup>1</sup> and Nagendra Singh<sup>2,\*</sup>**<sup>1</sup> *Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur- 303002, India*<sup>2</sup> *School of Biotechnology, Gautam Buddha University, Greater Noida- 201308, India*

Antimicrobial resistance occurs naturally over time due to changes at the genetic level of microorganisms. These microorganisms are present in food, animals, plants, humans, and the environment. Many pathogens can spread from people to people or from animals to humans. Some of the major drivers of the development of antimicrobial resistance are misuse (overuse, inappropriate selection and/or dosing, *etc.*) of antimicrobial agents, poor infection and disease management, lack of access to clean water, sanitation and hygiene for the people, poor access to affordable and quality drugs and diagnostics, lack of awareness and knowledge about health care, *etc.*

The global resistance among various pathogenic microbes to antimicrobial drugs is now becoming a serious threat to public health worldwide. The failure of treating microbial diseases is leading to prolonged illness and higher expenditure on healthcare along with a greater risk of life. Today, most infectious agents, including viruses, bacteria, fungi and parasites, have developed Multi-Drug Resistance (MDR), which is responsible for drastic increase in morbidity and mortality. In the last few decades, the administration of antibiotics has drastically increased due to a rapid rate of microbial infections; the latter owed to the emergence of MDR in various microbial strains. MDR is defined as a reduced sensitivity of a microbe to an antimicrobial drug that had been used effectively against the same microbe earlier. Such resistant organisms are able to combat the drug leading to ineffective treatment and increased persistence and spreading of the infection in an individual or population.

Antibiotics are a class of chemotherapeutic agents used in the clinical management of microbial infections. Although antibiotics have been used as magic bullets for curing various bacterial infections, their benefits are diminished due to the global emergence of resistant bacterial strains. The term antibiotics was

---

\* **Corresponding author Nagendra Singh:** School of Biotechnology, Gautam Buddha University, Greater Noida-201308, India; E-mail: nagendratomar@gmail.com

first coined by Selman Walksman, an American microbiologist, for compounds that inhibit the growth of microorganisms [1]. The modern era of antibiotics started in 1928 with the discovery of penicillin from the culture of the fungus *Penicillium notatum* by Alexander Fleming, a British doctor. Although the development of antibiotic resistance is mainly attributed to the imprudent and excessive usage of antibiotics, both biosynthetic antibiotic as well as resistance-conferring genes have been known to have evolved much before the use of antibiotics [2 - 5]. The natural occurrence of antibiotics in sub-inhibitory amounts acts as signaling molecules for quorum sensing, biofilm formation, and in production of virulence factors. The elucidation of the precise roles and mechanisms of antibiotics still remains to be understood. Antibiotics are secondary metabolites of microorganisms that are produced in a very low concentration during the late stages of the stationary growth phase. The drastically different roles of antibiotics have been explored in natural conditions in comparison to the high doses used for therapeutic purposes against microbes. Nutrient starvation induces microbes to produce a large array of small compounds called parvomes [6]. So far, only a small fraction of parvomes has been characterized as antimicrobial agents.

WHO has reported rapid MDR emergence in *E. coli*, *K. pneumonia*, *S. pneumonia*, *Mycobacterium tuberculosis* and species of *Salmonella* and *Shigella* spp. for a number of antibiotic molecules [7]. Various fungi such as *Candida*, *Aspergillus* spp., *Cryptococcus neoformans*, *Trichosporon beigeli*, *Scopulariopsis* spp., and *Pseudallescheria boydii* have been reported as resistant against drugs such as polyene macrolides, azole derivatives, nucleotide synthesis inhibitors and 1,3- $\beta$ -glucan synthase inhibitors [7, 8]. An extended exposure to antiviral drugs has made viruses also resistant in immunocompromised people. MDR has been observed in several viruses such as cytomegalovirus (CMV), herpes simplex (HSV), Varicella-Zoster (VZV), human immunodeficiency (HIV), influenza A, hepatitis C (HCV), and hepatitis B (HBV) viruses [9, 10]. MDR emergence has also been reported in several parasites, including *Plasmodium* spp., *Leishmania* spp., *Entamoeba* spp., *Trichomonas vaginalis*, *Schistosoma* spp. and *Toxoplasma gondii* for drugs such as pentavalent antimonials, miltefosine, chloroquine, artemisinin, paromomycin, amphotericin B, atovaquone, sulfadiazine and pyrimethamine [11 - 19].

Most of the infectious organisms have developed high level of alarming MDR against many commonly used antibiotics, being called “super bugs”. Examples of super bugs include MDR bacteria causing urinary tract infections, skin infections and pneumonia. Resistance is known to be a naturally occurring process. A lot of research is currently being performed in order to gain better understanding of resistance mechanisms, which will further aid in tackling the resistant microbes.

The emergence of MDR is a serious threat to society in the current era, since influenza, HIV, tuberculosis, pneumonia, yeast infections and other diseases are major causes of mortality. As per the WHO's update, in 2018, 3.5% new cases and 18% old cases of tuberculosis in the world are estimated to present MDR. About 8.5% of MDR cases showed extensive drug resistance (XDR) tuberculosis. Over 40,000 cases of XDR-TB cases are projected to be emerging every year. MDR-TB is caused by bacteria that do not respond to at least two of the most potent drugs, isoniazid and rifampicin. Pneumonia is one of the most common infections globally. MDR Gram negative bacteria (MDR-GNB) are responsible for serious threats to the health care system. The most common *Enterobacteriaceae* isolated from patients with pneumonia were found to be *Klebsiella pneumoniae*, *Enterobacter* spp. and *Escherichia coli*, which accounted for 12%, 8%, and 7%, respectively, of all bacterial isolates included in a study [20]. Antiretroviral therapy for HIV also faces severe challenges due to the development of resistance. Similarly, malaria parasites have also been observed to be resistant to several drugs such as chloroquine, artemisinin, and pyrimethamine [18].

In recent times, infections by MDR microbes have become a big issue in public healthcare management. The overuse or misuse of antibiotic agents in the last few decades is responsible for the emergence of several MDR strains of bacteria, viruses, fungi and parasites. A rapid increase of severe systemic infections along with the development and spread of resistant pathogens are creating a serious challenge to the current healthcare system. Regrettably, so far, the efforts to develop new drugs have not been sufficient to tackle the emergence of new MDR strains. Along with implementing social awareness programs, there is an urgent need to understand the development of resistance mechanisms to find a therapeutic solution for the MDR microorganisms.

#### **CONSENT FOR PUBLICATION**

Not applicable.

#### **CONFLICT OF INTEREST**

The authors declare no conflict of interest, financial or otherwise.

#### **ACKNOWLEDGEMENTS**

Declared none.

#### **REFERENCES**

- [1] Waksman SA. The role of antibiotics in nature. *Perspect Biol Med* 1961; 4(3): 271-87. [<http://dx.doi.org/10.1353/pbm.1961.0001>]

## Development of Drug Resistance

**Divyapriya Karthikeyan<sup>1</sup>, Mukesh Kumar<sup>2</sup>, Jyoti Yadav<sup>4</sup>, Amit Alok<sup>3</sup>, Kishore K. R. Tetala<sup>1</sup> and Sanjit Kumar<sup>1,\*</sup>**

<sup>1</sup> *Centre for Bioseparation Technology (CBST), Vellore Institute of Technology (VIT), Vellore 632014, Tamil Nadu, India*

<sup>2</sup> *Department of Biophysics, All India Institute of Medical Sciences, New Delhi, 110029, India*

<sup>3</sup> *Division of Radiation Biodosimetry, Institute of Nuclear Medicine and Allied Sciences, Timarpur, Delhi, 110054, India*

<sup>4</sup> *Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur-303002, India*

**Abstract:** The phenomenon of drug resistance is a widely acknowledged problem in clinics. Drug resistance not only increases the treatment time, but also paves the way for testing the maximum limit of dose tolerance of antibiotics in the patient. There is no escaping of the fact that drug tolerance may remain a perpetual problem and bacteria will keep on evolving as a part of the natural selection process. Therefore, novel drugs targeting the novel mechanism of action could be a proposed solution for this problem. The mechanism of action includes efflux pump, alteration/modification of drug target, enzyme inactivation and prevention of drug penetration. The other thing is to avoid the unnecessary usage of antibiotics so that the bacteria living inside the body do not develop resistance. The places where antibiotics can be bought for human or animal use without a prescription, the emergence and spread of resistance are made worse. Similarly, in countries without standard treatment guidelines, antibiotics are often over-prescribed by health workers and veterinarians and over-used by the public. Therefore, this unregulated overuse of antibiotics may lead to an era where normal infection may become difficult to treat and could lead to mortality. The maintenance of hygiene is a must for everyone and it is the only way to get rid of pathogenic bacteria. So, in this chapter, we summarize recent literature on the development of drug resistance, their mechanism of actions used by microbes to develop antibiotic resistance, factors determining their development by infective agents and the spread of resistant bacteria.

**Keywords:** Antibiotics, Bacteria, Drug resistance.

### INTRODUCTION

Drug resistance means the development of mechanisms to show less or lack of sensitivity to a particular drug or drug family. From a medical point of view, the

---

\* **Corresponding author Sanjit Kumar:** Centre for Bioseparation Technology (CBST), Vellore Institute of Technology (VIT), Vellore 632014, Tamil Nadu, India; E-mail: sanjitkroy@gmail.com

increase of resistant bacterial strains is an alarming issue but at the same time, it validates the theory of adaptation in evolution. The first actual antibiotic was first discovered by Sir Alexander Fleming [1], and since then, it has been used throughout the world in medicine and plays an essential role in fighting microorganisms [2]. However, excessive use of antibiotics generated multi-resistant bacteria which pose, in recent years, a serious threat to human life [3]. A newer set of antibiotics is required to treat infections that were treated easily in the past. Bacteria surviving the hospital setup are normally drug-resistant and often require strong antibiotics with prolonged administration. Antibiotic resistance is emerging as one of the global problems to human and animal health. One year of exposure to antibacterial agents also developed resistance in many bacterial species. This is due to the constant evolution of microbes to overcome the antimicrobial compounds produced by other microorganisms and synthetic compounds [4]. The evolutionary history of pathogens reveals that antibiotics have played a pivotal role in their evolution [5]. Several important factors can accelerate the evolution of drug-resistant microbes. These include the sub-therapeutic dosing, misuse and overuse of antimicrobials, and patient noncompliance with the recommended course of treatment. This resistance develops over the due course of time due to survival mechanisms adopted by pathogen against a drug or, to a lesser extent, change in the receptor activity of a host [6, 7]. Extended usage of antibiotics has resulted in the emergence of antibiotic-resistant bacteria, which are often difficult to eradicate requiring either a higher dose or a new class of antibiotics [8].

There are several strategies used by microbes to develop antibiotic resistance which falls into the four categories such as efflux pump, alteration/modification of drug target, enzyme inactivation and prevention of drug penetration (Table 1). Although intrinsic resistance utilises efflux pump, enzyme inactivation and limited uptake of drugs and acquired resistance utilises may be drug target modification, efflux pump and enzymatic inactivation [9].

**Table 1. Mechanism of drug resistance.**

S.No.	Mechanism of Drug Resistance	Drug Resistant Agents
1	Efflux pump	Fluoroquinolones, aminoglycosides, tetracycline, $\beta$ -lactams, macrolides
2	Alteration/modification of drug target	Fluoroquinolones, rifamycins, vancomycin, $\beta$ -lactams, $\beta$ -lactams, aminoglycosides
3	Enzyme inactivation	$\beta$ -lactams, macrolides, $\beta$ -lactams, macrolides, rifamycins
4	Prevention of drug penetration	$\beta$ -lactams, tetracycline, fluoroquinolones



Antibiotic resistant bacteria can modify their active site where antibiotics act, evolving a novel survival strategy [10, 11]. Researchers have also found several shreds of evidence where these microbes have an ability to inhibit the accumulation of antibiotics, thereby decreasing their effective concentration inside the bacterial cell. Bacteria produce efflux pumps to transport various antibiotic molecules. The efflux pump also flushes out antibiotics and prevent the accumulation of drug, thus, rendering bacterial resistance [12, 13]. Frequent mutations in the bacterial DNA can make the bacteria produce more pump molecules, increasing resistance. Bacteria also can change their membrane permeability. Membranes have pores that allow the transportation of molecules; thus, decreasing the permeability would mean lesser uptake of antibiotics [14, 15].

Bacteria seem to be an advanced version of this theory as some of them have developed an ability to produce enzymes that degrade antibiotics [11, 16]. Penicillin is known as the first discovered antibiotic and certain bacteria produce beta-lactamase enzymes, which degrade the beta-lactam ring of penicillin to inactivate it [17]. Some bacteria produce enzymes that are capable of adding a different chemical group to the antibiotic molecule, preventing binding between the antibiotic and its cell target. For example, *Mycobacterium tuberculosis* produces a protein that mimics the structure of DNA and this protein binds to fluoroquinolone antibiotics, thus preventing them from binding to the bacterial DNA. This property makes *M. tuberculosis* resistant to fluoroquinolones, sulphonamides, trimethoprim and DNA gyrase [18, 19].

Microbial resistance can occur in another manner when an antimicrobial drug functions as an antimetabolite by targeting a specific enzyme to inhibit its activity [20, 21]. First, bacteria may overproduce the enzymes, which are the drug targets and these target carry out enzymatic reactions. Secondly, the cell wall of bacteria develop a bypass mechanism which is not susceptible to binding of the antibiotics. Both of these strategies have been found as mechanisms of sulfonamide resistance [22, 23].

Many antibiotics act on a bacterial target (usually a protein), inactivating its activity. Some bacteria produce DNA mutations that modify the target so that these drugs may not bind to it [24]. Some bacteria add different chemical groups to the target, thus, shielding themselves from antibiotics, while some other bacteria express alternative proteins which can be used to inhibit the action of antibiotics. Hence, *Staphylococcus aureus* can produce a new penicillin-binding protein by acquiring the resistance gene *mecA* [25].

The targets of  $\beta$ -lactam antibiotics are proteins required for bacterial cell wall synthesis. This type of resistance is the basis of MRSA (methicillin-resistant

---

**CHAPTER 3**

---

**Current Challenges in Treating MDR**

**Vaishali Gurjar<sup>1</sup>, Ayushi Khurana<sup>1</sup>, Gunjan Shaily<sup>1</sup>, Sanket Kaushik<sup>2</sup> and Nagendra Singh<sup>1,\*</sup>**

<sup>1</sup> School of Biotechnology, Gautam Buddha University, Greater Noida, India

<sup>2</sup> Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur- 303002, India

**Abstract:** Multiple-Drug Resistance (MDR) is a mechanism that renders the ineffectiveness of one or more than one antimicrobial agents shown by disease causing microorganisms. MDR has become one of the major public health challenges as initially, the MDR species were restricted only to hospitals, but now they are found everywhere. Due to the slow advancements in the discovery of new or different antibiotics against the MDR organisms, the medical society is facing great challenges in the treatment of infections caused by resistant microorganisms. This chapter outlines the challenges involved in drug discovery, and treatment to fight and prevent MDR infections.

**Keywords:** Antibiotics, Drugs, MDR, Microorganisms, Pathogens, Proteins.

## INTRODUCTION

MDR infectious microorganisms are the most threatening species to the public health as the infections caused by these organisms cannot be treated by first line antibiotics, thus resulting in more expensive and long-lasting treatments, *e.g.*, MDR-tuberculosis (TB). MDR is antimicrobial resistance expressed by a microbial species to at least one drug out of three or more antimicrobial categories [1]. Along with MDR bacteria, MDR viruses and parasites are also among the most threatening challenges to public health. Extensive drug resistance (XDR) is a new term given to microbes that are resistant to all antimicrobial agents except two or less antimicrobial categories with different chemical structures [2 - 4].

Thus, it results in a prolonged infection time and, also, adds an increased risk of infection spread. More expensive treatment options fallout with the emergence of

---

\* **Corresponding author Nagendra Singh:** School of Biotechnology, Gautam Buddha University, Greater Noida-201308, India; E-mail: nagendratomar@gmail.com

MDR against commercially available drugs. The evolution of global trades and tourism has increased the risk of MDR spread all over world. It is important to cutdown the use of antimicrobial agents to the lowest possible levels to reduce the risk of resistant microbes. The development of novel categories of antimicrobial agents is also desired to tackle MDR pathogens. The Infectious Diseases Society of America (IDSA) has recognized antimicrobial resistance as “one of the greatest threats to human health worldwide.” MDR has a crucial impact on the lives of immunocompromised patients and has been associated with increased mortality rates. A rise in MDR has challenged all the aspects of drug designing [5, 6].

The drugs which are designed to treat a disease are target specific, any mutation in these target sites reduces the effectiveness of the particular drug, further causing antibiotic resistance. Second, the development of MDR is related to the intake of broad-spectrum antibiotics for empirical as well as definitive therapy. There are two categories of drug resistance:

#### **Natural/Intrinsic Resistance**

Few microbes show resistance towards certain drugs as they lack the metabolic process or the target sites affected by drugs. For example, vancomycin, due to its large size, cannot enter Gram-negative bacteria, as drugs in these bacteria enter through small size porins. Intrinsic resistance is also acquired by *Mycobacterium tuberculosis* for fluoroquinolones, tetracycline, aminoglycosides drugs due to the presence of efflux pumps [7].

#### **Acquired Resistance**

In a few microbes, drug resistance develops due to the consistent use of antimicrobial agents (AMA) over a period of time and or non compliance with the drug regimen. Thus, the acquired resistance depends upon the particular microorganism and the drug as well. For *e.g.*, *Staphylococci*, coliforms, and *Tubercle bacilli* are notorious microbes for rapid acquisition of resistance. Resistance in microbes may be developed by mutation (vertical transfer) or horizontal gene transfer. MDR in Mtb has been reported due to mutations, expression of genes encoding new proteins, or drug inactivating enzymes under the selection pressure of antibiotics [8].

### **MECHANISMS OF MDR DEVELOPMENT**

Many microorganisms survive by developing adaptability to the antibiotic agents by altering their genetic makeup. Spontaneous mutations are introduced in the DNA of the microbes in order to nullify the effects of the antimicrobial agents.

This enables some bacteria to resist the activity of certain antibiotics to develop drug resistance. The mutated genes are also transferred to other microbes to make them resistant. MDR Organisms (MDROs) employ one or more mechanisms to become resistant to antibiotics.

### **Alteration of the Target Protein by Mutation**

Mutation of a gene affected by a drug, rendering the drug ineffective, is a common way of developing resistance. The drug target site is altered as a result of spontaneous mutation of the bacterial gene on the chromosome, which gets selected in the presence of the antibiotic drug. Rifamycins and quinilones have been shown to be ineffective by mutations in the RNA polymerase and DNA gyrase genes, respectively. The resistance may also get acquired by the transfer of altered genes from one microorganism to another by transformation, conjugation or transduction, such as the acquisition of *mecA* genes responsible for methicillin resistance in *Staphylococcus aureus*.

Another example of drug resistance by the mutational changes is resistance to oxazolidinones (linezolid and tedizolid). These drugs are bacteriostatic antibiotics having a broad Gram-positive activity by binding to the A site of bacterial ribosomes and inhibiting the translation process. The mechanisms of linezolid resistance include mutations in genes encoding the domain V of the 23S rRNA and/or the ribosomal proteins L3 and L4 (rplC and rplD, respectively), and methylation of A2503 in the 23S rRNA mediated by the Cfr enzyme as modification in ribosome modulates its susceptibility to antibiotics [9].

### **Modifications of the Drug**

One of the best bacterial strategies to develop resistance is by producing enzymes that act upon the drug and inactivate it either by its chemical modifications or by its complete destruction, rendering the drug unable to interact with target molecules.

Synthesis of enzymes responsible for chemical alteration of the drug is a well understood mechanism of acquiring resistance in both Gram-negative and Gram-positive bacteria. The most frequent biochemical alteration reactions catalysed by such enzymes are acetylation (*e.g.*, aminoglycosides, chloramphenicol, streptogramins), phosphorylation (*e.g.*, aminoglycosides, chloramphenicol), and adenylation (*e.g.*, aminoglycosides, lincosamides). The resultant reaction of target modification is hindrance in the drug binding, leading to higher bacterial minimal inhibitory concentrations (MICs) of the drugs. One of the best studied examples of this category is the presence of aminoglycoside modifying enzymes (AMEs) which catalyse covalent modification of hydroxyl or amino group of

---

**CHAPTER 4**

---

**Methods of Detection of MDR****Monish Bisen<sup>1</sup>, Anupam Jyoti<sup>2</sup> and Juhi Saxena<sup>2,\*</sup>**<sup>1</sup> Faculty of Applied Sciences and Biotechnology, Shoolini University of Biotechnology and Management Sciences, Bajhol, Solan, Himachal Pradesh 173229, India<sup>2</sup> Department of Biotechnology, University Institute of Biotechnology, Chandigarh University, Mohali, Punjab, 140413, India

**Abstract:** World health organization (WHO) has acknowledged the problem of multi-drug resistance (MDR) bacteria as an endemic and widespread problem globally. MDR in LMICs represents one of the biggest threats to global health and is one of the greatest current challenges in infectious disease research. High mortality/morbidity rates of MDR infections are mainly due to the lack of timely, rapid detection and treatment of the causative pathogen. Molecular mechanism conferring MDR against most common treatment options includes mutations in antibiotics' susceptible genes at one or many sites. A number of methods, including culture-based, nucleic acid-based amplification of resistance conferring genes, and immunological based assays have been developed to detect MDR. Each method has defined specificity, sensitivity and time around to detect MDR infections in clinical settings.

**Keywords:** Antimicrobial Resistance, Detection of MDR, Multi-drug resistance bacteria (MDR), MDR infections.

**INTRODUCTION**

Emergence of multi-drug resistance bacteria (MDR) is a serious threat to global health care system. These 'superbugs' are ubiquitously present, causing mortality worldwide. Pathogen showing insensitivity to at least one in three or more antimicrobial categories is termed to be MDR. The development of resistant strains is explained well by natural selection theory. Irrational use of antibiotics, poor sanitation, inapt food and hygiene practices cause sensitive bacteria to divide and mutate. Such mutated strains transfer their resistant genes over the generations (Table 1). Infections due to MDR bacteria are of serious concern as

---

\* **Corresponding author Juhi Saxena:** Department of Biotechnology, University Institute of Biotechnology, Chandigarh University, Mohali, Punjab, 140413, India; E-mail: jina.saxena@gmail.com

very few treatment options are available with current antibiotic therapy. Moreover, such mutated strains are the main culprits for the spread and outbreak of antibiotic resistance. Penicillin-resistant *Streptococcus pneumoniae*, Methicillin-resistant *Staphylococcus aureus* are common Gram-positive bacteria. Vancomycin-Resistant *Enterococci*, Extended-spectrum  $\beta$ -lactamase *Klebsiella pneumoniae* (carbapenemase) represent Gram-negatives. Including bacteria, all other infectious agents like viruses, fungi, parasites, protozoans are capable of developing and spreading antimicrobial resistance. In primary, secondary or clinical MDR, the problems get terribly worse in the immune comprised host, subsequently leading to persistent illness and high therapeutic cost [1].

**Table 1. Prevalent drug-resistant microbes.**


S. No	Name of Bacterium	Drug	Genes	References
1.	<i>Escherichia coli</i>	Carbapenem and Cephalosporins	<i>Tem</i>	[3]
2.	<i>Enterobacter spp.</i>	Carbapenem	<i>Tem</i>	[4]
3.	<i>Klebsiella spp.</i>	Carbapenem, Colistin, and Cephalosporins	<i>tem, ctxM, vanB, shv, blaKPC1</i>	[5]
4.	<i>Acinetobacter baumannii</i>	Carbapenem	<i>Tem</i>	[6]
5.	<i>Pseudomonas aeruginosa</i>	Carbapenem	<i>Tem</i>	[7]
6.	<i>Staphylococcus aureus</i>	Methicillin	<i>vanA, mec</i>	[8]
7.	<i>Enterococcus faecium</i>	Vancomycin	<i>vanB, vanC</i>	[9]
8.	<i>Salmonella Typhi</i>	Fluoroquinolone	<i>invA, hilA</i>	[10]
9.	<i>Streptococcus pneumoniae</i>	Penicillin	<i>parC, gyrA</i>	[11]
10.	<i>Neisseria gonorrhoeae</i>	Cephalosporins	<i>gyrA</i>	[12]
11.	<i>Mycobacterium tuberculosis</i>	Rifampicin, isoniazid, and fluoroquinolone	<i>katG, rpoB</i>	[13]

MDR bacteria have shown a myriad of strategies to reduce the efficacy of available drugs. Genetic mutations, exchange of plasmid or chromosomal genes, reformed cell wall composition and permeability, target proteins or enzymes modifications, efflux pumps, enzymatic antimicrobial inactivation or transformation are some of them. As per the WHO's reports (2020), the mortal combat against these multi-drug resistance bacteria is a big concern and presents a multitude of challenges with very few effective and innovative antibiotics. By 2050, no treatment options will be available against these MDR bacteria. Looking at the present scenario, immediate screening of drug resistance and new alternatives for treatment hold paramount significance [2].

\*According to a report on anti-tuberculosis drug resistance in the world prepared by the WHO/IUATLD Global Project on anti-tuberculosis drug-resistance surveillance, MDR-TB has reached rates of up to 14% among new patients and up to 50% in previously-treated patients in some contexts (World Health Organization, 2004).

## TECHNIQUES TO DETECT MDR

A number of techniques have been devised to detect MDR bacteria. This chapter will evaluate the different methods to detect MDR pathogens (Fig. 1).



**Fig. (1).** Different methods to detect multi-drug resistance (MDR) along with their detection time range. PCR: Polymerase Chain Reaction; LFIA: Lateral Flow Immuno-Assay; WGS: Whole Gene Sequencing. See text for details.

### Culture

Culture based methods are the gold standard for not only identification but also for the detection of MDR bacteria. Identification of bacteria is the first step in the antibacterial susceptibility test (AST). This is done by microdilution of suspected blood followed by plating to obtain a pure culture of bacteria. The bacteria are identified by Gram staining and biochemical tests as standard methods. After identification, bacteria are subjected to AST, where bacterial isolates are allowed to grow in the presence of a known concentration of antibiotics and their growth is monitored by visual detection. Nowadays, various AST cards and wells having known concentration of specific antibiotics are commercially available, which monitor the growth as well as resistivity/sensitivity pattern of bacteria against antibiotics. Despite this, culture based MDR detection method takes 3 to 5 days to get a conclusive result, and by that time, patients are administered broad-spectrum antibiotics, which further leads to the development of MDR and poor patient outcome. Hence, newer methods have been developed to improve the sensitivity and specificity as well as reduce the sample processing and MDR detection time [14].



---

**CHAPTER 5**

---

**Molecular Probes as Diagnostic Tools****Anurag Jyoti<sup>1,\*</sup> and Rajesh Singh Tomar<sup>1</sup>**<sup>1</sup> *Amity Institute of Biotechnology, Amity University Madhya Pradesh, Maharajpura Dang, Gwalior-474005, M.P., India*

**Abstract:** Diseases caused by pathogenic microbes have been a serious problem since decades. They often cause high mortality in both developing and developed countries. Diseases including diarrhea, cholera, typhoid, *etc.*, are often involved in outbreaks related to pathogens surviving in water. In recent years, the management of infectious diseases has drawn much attention among scientists and researchers. Various specific, sensitive and reproducible detection methods have been developed to identify pathogen contamination in water. These advanced methods generally use probes for diagnostics of pathogens. The present chapter attempts to focus on the development of various probe chemistries for the detection of pathogens. We also intend to present here the pros and cons of different methods.

**Keywords:** Amplification, Annealing, Culture, Enumeration, Fluorescence, Infectious disease, Microscopic examination, Molecular Techniques, Mortality, Outbreaks, PCR, Probe, Quantification, Quencher, Real Time PCR, SYBR GREEN1, Sensitivity, Specificity, Template, Target.

**INTRODUCTION**

Increased population and urbanization have posed challenges to the management of infectious diseases. Water-borne infectious diseases cause major outbreaks in both developing and developed countries. These include diarrhoea, typhoid, cholera and other gastrointestinal diseases [1, 2]. Management of infectious diseases requires several measures. Identification of causative pathogens at the initial level is helpful in the therapeutic regimen of disease. A number of methods exist for the detection of pathogens, including culture-dependent and culture independent methods. All these methods have their own pros and cons. Culture-dependent methods are time consuming and labour intensive. In most laboratory setups, the disease is diagnosed on the basis of microscopic examination of culture. These methods are generally qualitative and, therefore, not applicable for

---

\* **Corresponding author Anurag Jyoti:** Amity Institute of Biotechnology, Amity University Madhya Pradesh, Maharajpura Dang, Gwalior-474005, M.P., India; E-mails: [ajyoti@gwa.amity.edu](mailto:ajyoti@gwa.amity.edu), [anurag.bt@gmail.com](mailto:anurag.bt@gmail.com)

disease management. With the span of time, molecular methods have been established and have found their applicability in diagnostics. Polymerase Chain Reaction (PCR) has been established as a standard method for the detection of pathogens. It works on the basis of *in-vitro* amplification of genes or a piece of genes using specific primer pairs. Since this method uses explicit DNA sequences, it is highly specific. Immunological techniques, such as Enzyme Linked Immunosorbent Assay (ELISA), are based on the interaction between antigen-antibody and often get limited due to non-specificity and cross-reactivity.

The development of drug-resistance among causative agents has further complicated the detection system. Various methods, including phenotypic and genotypic methods, are currently used for the quantification of these pathogens. In most of the studies, drug-resistance pattern has been performed using the standard disc-diffusion method using the Clinical Laboratory Standard Institute (CLSI) guidelines, which often give inaccurate results.

Since the last decade, Real Time/Quantitative Polymerase Chain Reaction (RTi-PCR)-based assays have been established as the gold standard in the field of pathogen diagnostics [3, 4]. The method uses molecular probes in addition to the primer pairs. Various probe chemistries are evolved to detect and quantify pathogens present in the sample. The limit of detection (LOD) of this method is very low; therefore, it is used for the diagnostic of pathogens in low doses. Variants of RTi-PCR have revolutionized the quantification of target DNA of pathogenic origin. With the advent of multiplexing, in one assay, enumeration of at least four pathogens can be achieved using different probe chemistries.

Molecular probe-based diagnostics have seen major breakthroughs, and at the same time, they face some challenges. Various methods are there that can reduce the detection time with high sensitivity, including ELISA, Polymerase Chain Reaction (PCR), and so on. Despite improvements, these methods still require more time, sophisticated instrumentation and complex sample preparation steps, which limit their use in diagnostics. In some instances, chances of false positive results occur in DNA amplification-based pathogen detection.

Pathogen detection using molecular probes has revolutionized the management of infectious diseases. The current chapter will provide an overview of the present scenario of molecular probes for pathogen diagnostics.

## **MOLECULAR DIAGNOSTICS FOR DETECTION OF DRUG-RESISTANT PATHOGENS**

Detection of disease-causing pathogens often demands accurate and specific methods. Conventional culture-based methods often face challenges of specificity,

sensitivity and rapidity. Classical molecular methods, such as PCR have established themselves in diagnostics. Still, sensitivity and quantification are major hurdles for these techniques and methods. With the advent of RTi-PCR and its various formats, the diagnostics of pathogens have been revolutionized, saving time with improved sensitivity and ease of quantification. Various probe chemistries have been used in RTi-PCR based diagnosis of pathogens.

Detection of drug-resistant pathogens is a real challenging task. Advancements of genome sequencing and identification of genes, responsible for drug-resistance and virulence has opened new avenue towards detection of these pathogens. The development of duplex PCR-based system has shown the potential to detect pathogens in low doses. Detection of virulent gene and drug-resistant genes simultaneously in single tube format gives quick results for the identification of pathogens.

### **Polymerase Chain Reactions (PCR)**

PCR is one of the most important disruptive technologies in molecular biology. DNA molecules are amplified in *in-vitro* conditions using specific primer pairs. Each round of PCR produces new double stranded DNA molecules. Primer pairs are designed using dedicated software to ensure specificity. Certain portions of DNA of the pathogen of interest are targeted and primers are designed accordingly. PCR consists of 3 major steps: Denaturation, Annealing and Extension. During denaturation, the double stranded (ds) DNA gets separated and will serve as templates for primers, while in annealing, the temperature is lowered down and both the primers and the DNA templates get aligned themselves at their respective complementary strands. During extension, each primer pair extends and generates a new pair of double stranded DNA. Two important factors impact the pathogen detection using PCR: a) Selection of conserved regions of genes, unique to the target organism and b) Optimization of annealing temperature for complete binding of primer pair with respective DNA template.

A number of studies exist that use PCR for the detection of pathogens. This includes pathogens causing diseases in plants, animals and human beings. Mirmajlessi *et al.* (2015) has presented review on detection of pathogens on strawberry using PCR [5]. Stockmann *et al.* (2015) has compared standard microbiologic testing with the multiplex polymerase chain reaction (PCR) system that simultaneously detects 23 diarrhoeal pathogens [6].

## **Real-Time PCR High-Resolution Melting Analysis**

**Ena Gupta<sup>1</sup>, Sanket Kaushik<sup>1</sup>, Vijay Kumar Srivastava<sup>1</sup>, Juhi Saxena<sup>2</sup> and Anupam Jyoti<sup>2,\*</sup>**

<sup>1</sup> *Amity Institute of Biotechnology, Amity University Rajasthan, Amity Education Valley, Kant Kalwar, NH-11C, Jaipur-Delhi Highway, Jaipur, India*

<sup>2</sup> *Department of Biotechnology, University Institute of Biotechnology, Chandigarh University, Mohali, Punjab, 140413, India*

**Abstract:** High Resolution Melting (HRM) is a homogeneous, exceptionally incredible innovation for single nucleotide polymorphism (SNP) genotyping, mutation scanning and sequence scanning in DNA samples. HRM analysis works on the principle of melting (dissociation) curve methodologies of Polymerase Chain Reaction (PCR) empowered by the new accessibility of improved double-stranded DNA (dsDNA)–binding dyes and next-generation real-time PCR instrumentation. The HRM technology portrays samples of nucleic acids on the basis of their disassociation behaviors and identifies the differences in even the short sequence in amplified PCR products, just by direct melting. Samples are further distinguished according to the length of their sequence, GC content and strand complementarity. Indeed, even a single change in the base pair in the sequences of DNA samples causes differences in the HRM curve. The difference in the melting curves of different genetic sequences at distinct rates can be observed, detected and compared using these curves. Development of the melting curves after HRM analysis is basically plotted with temperature on the X axis and fluorescence on the Y axis, which resembles the real-time PCR amplification curve but with the difference of temperature for cycle number. With the use of different DNA dyes, high-end instrumentation and sophisticated analysis software, these distinctions are detected.

**Keywords:** Antimicrobial resistance, Genotyping, Genetic variants, HRMA, Intercalating dyes, Melting curve.

### **INTRODUCTION**

Because of the high demand for brisk, highly-throughput examination and genetic study of microbes in addition to data handling and research, focus should be on

---

\* **Corresponding author Anupam Jyoti:** Department of Biotechnology, University Institute of Biotechnology, Chandigarh University, Mohali, Punjab, 140413, India;  
E-mail: anupam.e12214@cumail.in

the significant interpretation and improvement of advanced mechanism of detection that counteracts the requirement for electrophoretic analysis, decrease the exposure of contamination and significantly reduce labor time and reagent expenses [1]. Thus, new advances in methods, instruments, fluorescent dyes and different operating systems for melting analysis of DNA have devised a more flexible novel technique for an alternative scanning and genotyping, *i.e.*, a comparatively novel approach of post-PCR analysis allowing the analysis of characterization of PCR amplicons in a closed structure [2].

Earlier analysis of the melting curves of PCR product together along-with real-time was recommended with the Light Cyclers [3]. No processing or separations were required like many DNA analysis methods. The DNA duplexes resistance was scanned as the temperature was increased in the solution by the fluorescence of SYBRs Green I. Even though large variation in PCR products was differentiated by melting temperature ( $T_m$ ), refined sequence fluctuations were considered beyond the reach of fluorescent melting analysis. HRMA (high resolution DNA melting) was initially reported in 2002, and it has since been widely utilised as a research tool [4] and as a quick approach for genotyping known variations or scanning for undiscovered variants [5].

HRMA is logical, economical and rapid approach that requires labelled probes. The sensitivity of heterozygote scanning reaches 100% with the expansion of saturating dye prior to PCR and rapid melting curve analysis of the amplicons. To reduce the burden of sequencing, researchers might examine common heterogeneity with the melting of shorter amplicons and unlabeled probes. Different heterozygotes create comparable melting curves, but unlike homozygous variants, they do not discriminate [2].

For discerning variances and heterogeneity in nucleic acid sequencing, HRM analysis is a more sophisticated, inventive, robust, and closed-tube, high-throughput method [6, 7]. HRM allows for the discovery of genetic variants by analysing PCR melting curves of DNA with spectacular temperature resolution while using a saturating DNA-binding dye of high grade and advanced instrumentation software [6]. Its procedures also create unique and sensitive melting profiles, which may be used in genotyping, mutation screening, and methylation studies using heterozygosity, length, and GC content [8]. HRM utilizes cheap dyes and needs low optimization that works on similar platforms like TaqMan along with fluorescence resonance energy transfer (FRET) probes. HRM, on comparison to such approaches, gives better results as it is uncomplicated, coherent and more economical way to characterize more than one sample. HRMA is an elementary PCR that lacks the necessity for any big alterations in the laboratory with any specific skills. It performs under customized

conditions in a close vicinity of a specific dye. The most expensive element is the recovery of the instrument [9].

To some extent, HRM is a recent post-PCR approach that analyses the shape of the melting curve followed by amplification of PCR with saturating DNA dye, resulting in a specific amplicon melting curve, allowing the detection of small sequence variants. The present technique is obsolete used effectively for mutation scanning, SNPs genotyping, and identifying several bacterial species, as well as screening for drug resistance in pathogens [10 - 12]. Besides genotyping, HRM real-time PCR has been revealed to have an interesting capability of SNP identification across the genes which are involved in drug resistance [13]. Many researches have demonstrated HRM real-time PCR for the identification of mutations associated with drug resistance throughout the last decade. Resistant to antibiotics is assessed by utilizing culture based techniques *i.e.* the agar percentage methods or liquid media methods such as the BACTEC MGIT 960. However, these approaches are not efficient and need therapeutic susceptibility testing which takes at least a week, as they are effective [14]. It is clinically critical for patients to have an early drug susceptibility result in order to begin an appropriate therapeutic regimen that will result in improved outcomes. It also enables the monitoring of antibiotic resistance rates, which are important in the fight against infection [15].

## **PRINCIPLE OF THE MELTING PROFILE**

Various intercalating dyes are utilized by the Post-PCR melt curve analysis to identify primer-dimers or any other non-specific products. This process is known as Low Resolution Melting. While the temperature rises, a curve is generated in increments with 0.5 °C, thus constantly denaturing of an amplified DNA target. The dye used is primarily fluorescent, but when the duplex DNA is denatured, the fluorescence gradually decreases when attached to dsDNA. The length, GC content, sequencing, and heterozygosity of the amplified target all influence the melting profile [16].

At the melting temperature of a DNA sample, the highest rate of fluorescence declination is usually measured. As a result, the temperature at which half of a DNA sample is double stranded and the other half is single stranded is known as the  $T_m$  temperature. For fragmented DNA that is longer and/or has a higher GC content, the  $T_m$  temperature is generally greater [17]. By analyzing the curve of fluorescence *vs.* Temperature ( $-dF/dT$  versus  $T$ ), data from weak fluorescence resolution melting curves may be utilised to determine the temperature (Fig. 1).

Rise in the temperature during a low-resolution melt curve analysis is in 0.5 °C steps and this is reduced to 0.008 - 0.2 °C increments for HRM analysis. That is

## Current Therapeutic Options and Challenges for MDR

Aakanksha Kalra<sup>1</sup>, Sakshi Piplani<sup>2</sup> and Ravi Ranjan Kumar Niraj<sup>3,\*</sup>

<sup>1</sup> Dr B. Lal Institute of Biotechnology, Jaipur, 302017, India

<sup>2</sup> Vaxine Pty Ltd, Warradale, Australia; College of Medicine and Public Health, Flinders University, Adelaide, Australia

<sup>3</sup> Amity Institute of Biotechnology Amity University Rajasthan, Jaipur, 303002, India

**Abstract:** Multiple-Drug Resistance (MDR) against many antibiotics and other therapeutic agents is a major concern for health care providers and researchers in the field. Due to tremendous rise in MDR cases, researchers are in search of potent therapeutic options or alternatives to overcome MDR. Here, in this chapter, we will discuss the current status of the common as well as advanced methods which have been developed so far for the treatment of MDR and also the challenges and opportunities in each of those methods. This chapter discusses common methods used for the treatment of MDR, *i.e.*, major antibiotics used for the treatment of MDR bacteria and synergistic approaches by the combination of different antibiotics. Along with common treatments used against MDR bacteria, this chapter also discusses current treatments like anti-microbial peptides, anti-virulence compounds, phage therapy and drug repurposing approaches for MDR treatment.

**Keywords:** Allopathic medicines, Anti-microbial peptide, Antibiotics, Carbapenems, Multiple-drug resistance, Phage therapy.

### INTRODUCTION

The relationship between bacterial species and humans is age old, with one affecting the other in their life cycle. Many bacterial species are essential part of the human body and its metabolism; they are referred to as the normal flora. However, many more have been identified as causative agents of numerous diseases. The use of traditional medicines and antibiotics for the cure of these infections has been consistent with emerging diseases and scientific advancements. However, the identification of novel antibiotics is being rendered

\* Corresponding author Ravi Ranjan Kumar Niraj: Amity Institute of Biotechnology Amity University Rajasthan, Jaipur, 303002, India; E-mail: rrkniraj@gmail.com



ineffective with the emerging resistance to the available drugs. This antibiotic resistance is increasing at a very rapid rate, thereby classifying the resistant bacteria into three different categories, *i.e.* multidrug resistant, extreme drug resistant and pan drug resistant. Considering the severity of the situation, drug resistance is one of the major thrusts in the health sector. The focus on drug resistance globally initiated in 2011, when WHO declared “combat drug resistance: no action today, no cure tomorrow” (WHO Report 2011). This was later revised in 2015 when World Health Organization focussed on all the aspects of drug resistance, including awareness and understanding of the antimicrobial resistance in addition to its prevention and cure. Needless to say, antimicrobial resistance (AMR) has become a global health concern in the present scenario. It has affected the global progress in multiple ways, which include affecting the economically weaker sections to a great extent, causing untreatable infections even in animals in turn affecting sustainable food production and affecting healthcare systems. According to the World Bank Group Report on Drug-Resistant Infections (March 2017), the economic burden of AMR is expected to rise to about US \$ 120 trillion by 2050, suggesting a dire and urgent need to focus on the issue [1]. The worldwide attempt to keep a check on the rising AMR was made in 2015 by WHO with the objective to create awareness, understanding, strengthening knowledge and evidence towards AMR; reducing the infection rates and optimizing antibiotic use of the antimicrobial agents. However, lack of funds has been the major cause of the huge difference in the national action planning vs. implementation. India is one of the countries enrolled in the Global Antimicrobial Resistance Surveillance System (GLASS) program to create awareness and keep a check on AMR. While understanding the mechanism of the emerging resistance, it has been observed that bacteria can evade the antimicrobial activity of antibiotics *via* three different but related mechanisms: resistance, tolerance and persistence. Therefore, this chapter is focussed on the current status of the traditional as well as advanced methods, which have been developed so far for the treatment of MDR and also the challenges involved in each of those methods.

## **TRADITIONAL METHODS USED FOR TREATMENT OF MDR**

It is a well-known fact that the number of bacteria on earth greatly outnumbers the total humans and many of them are causative agents of infectious diseases. Multiple approaches have been employed since ages for the treatment of these infections. which can mostly be categorized in home remedies; *i.e.*, Ayurveda/Unani systems of medicines, homeopathy and antibiotics. The first three systems of medicines are basically focussed on the symptom derived treatment rather than focusing on the pathogen involved. On the other hand, a wide range of antibiotics has been developed since the discovery of penicillin by

Alexander Fleming in 1928, most of which have been specific to the target bacterial species. This advent of antibiotics towards bacterial species, on the one hand, had overwhelmed all the existing systems of infection treatment back then and also revolutionized the treatment process for multiple infections, but, on the other hand, its misuse and overuse have led to the emergence of drug-resistant species. The more the number of antibiotics has been discovered, the greater the emerging resistance in isolates leading to the formation of multidrug (MDR), extensive drug (XDR) and pan-drug (PDR) resistant species. The ever-rising number of such species has urged a dire need for evaluation of existing and alternative strategies to combat them. The developed antibiotics as well as the ones in the development pipeline, are discussed in great detail in next section.

The use of plant-based traditional medicines for health care can be dated to as old as 200 BCE and are responsible for meeting healthcare needs across the world. For instance, healthcare needs up to 80% of African population and 40% of Chinese population are met *via* traditional medicines (WHO report 2002). The use of herbal formulations as antibiotics is gaining attention and mixed results have been obtained for the same. Certain studies have shown these formulations to be effective [2], while others have shown these formulations to be ineffective [3]. Medicinal extracts of various plants have been evaluated against resistant species of some of the most common pathogens, such as MRSA, *Klebsiella* spp., etc., and have shown promising results. Irrespective of the efficacy of the formulation, one of the most common side effects of these formulations is hepatotoxicity, which is observed due to unregulated doses of the formulations by oral route [4]. In spite of the above-mentioned concerns, the role of Ayurveda, medicinal plants and herbal formulations have been exploited as alternative strategies in the global market for a number of diseases. Together with home remedies, these alternatives have been the primary source of healthcare for a long time, but owing to their unascertained quality, lack of accurate chemical composition of the formulation, safety, efficacy, lack of regulation and unknown side effects, their use has been limited so far [3].

### **Major Antibiotics used for Treatment of MDR Bacteria**

The discovery of antibiotics has been a long journey, and, in the process, extensive classes of antibiotics have been exploited affecting different pathways of the bacterial life cycle. The latest generation of antibiotics that are in use are discussed in this section. Depending on their mechanism of action on the bacterial life cycle, the antibiotics have been classified in the following categories:

**CHAPTER 8****Phytomedicines for Bacterial Infections****Vijay Pal<sup>1</sup>, Ravneet Chug<sup>1</sup>, Kumar Sambhav Verma<sup>1</sup>, Priyal Sharma<sup>1</sup> and Vinod Singh Gour<sup>1,\*</sup>**<sup>1</sup> *Amity Institute of Biotechnology, Amity University Rajasthan, NH 11 C Kant Kalwar, Jaipur, India*

**Abstract:** Microbial pathogens have always been a great threat to many life forms, including human. To control microbial infection, especially bacterial infection antibiotics have been a boon. However, with the changing scenario, the bacteria have also evolved and developed resistance against many antibiotics and these pathogens have become more fatal. On the other hand, plants and plant products have been used as a natural resource to control these microbes. The plant seed oil has also been explored for the same; however, comparatively less literature is available on antimicrobial activities of seed oil derived from plants. Looking at the importance of seed oil in this field, the present review article presents a brief discussion about various aspects of seed oil and their application against bacteria.

**Keywords:** Multidrug resistance, Phytochemicals, Plants oil, Secondary metabolites, Traditional methods.

**INTRODUCTION**

The discovery of a wide range of antibiotics has been considered one of the biggest accomplishments in the field of medicine. These are pivotal for treating various bacterial infections in patients, including those undergoing surgery, in intensive care units, undergoing organ grafting or in cancer treatment [1, 2]. Antibiotics are generally target specific as they affect cell wall synthesis, DNA replication, and translational machinery of the bacterial cell. Alternatively, bacteria have also developed resistance mechanisms due to the increasing human population, overuse of antimicrobials, over prescription by clinicians, public perception, and behaviour (Non-prescription purchase, not completing the antibiotic dosage as prescribed by clinicians) and commercial pressure [3]. The development of antimicrobial resistance (AMR), which is a matter of grave concern as it results in the huge loss to individuals and economy [3, 4]. Antimicrobial resistance (AMR) has been identified by the World Health Organism-

\* **Corresponding author Vinod Singh Gour:** Amity Institute of Biotechnology, Amity University Rajasthan, NH 11 C Kant Kalwar, Jaipur India; E-mail: vkgaur@jpr.amity.edu

ation as a global threat because ~30,000 women and ~400,000 new-born babies lose their lives due to bacterial infection (WHO, 2016). According to the AR Threats (Report-2019 of CDC) antibiotic-resistant microorganisms can lead to > 2.8 million infections and 35,000 deaths in the United States each year [5]. Antibiotic resistance also increases the challenge of recalcitrant infections.

In today's era, the rapid emergence of multidrug resistance (MDR) in microorganisms is an increasing global crisis as it poses a challenge to the treatment of infectious diseases [2, 6]. This alarming situation has enforced the scientists and medical professionals to shift from broad-spectrum empirical therapy (use of known antibiotics), which are less effective against MDR bacteria, to the personalized and strategic approach [4]. Natural compounds have always been relied upon and widely searched for the novel drug discoveries for more than 5,000 years. Plants have been extensively used as a source of antibiotics, antineoplastic, analgesics, and cardioprotective. About 70–90% of the human population in developing countries still use medicines derived from plant extracts [3, 7, 8].

In the last two decades, many persistent efforts have been made to discover novel therapeutics for combating MDR. Natural products and their derivatives contribute to more than half of the Food and Drug Administration (FDA) approved drugs [3, 9]. A variety of plants extracts have antimicrobial properties [10]. These may be bactericidal as well as bacteriostatic against microbial flux pump, quorum sensing and bio-film formation [10].

Diterpenes, extracted from root bark of *Berberis aristata* were found to have antimicrobial properties against several bacterial strains including *Enterococcus faecalis*, *Staphylococcus spp.*, *Escherichia coli*, *Klebsiella spp.*, *Pseudomonas aeruginosa*, *Salmonella spp.*, *Shigella flexneri* at a low concentration (0.05–5 mg/mL) at the same time these diterpenes had IC<sub>50</sub> value of 245 to 473 µg/mL against L20B, RD and Hep 2 cell lines, indicating higher biosafety level [11]. Similar to this Arora and Sood (2017) [12] reported the leaf extracts of *Gymnema sylvestre* to have antimicrobial activities against *Klebsiella pneumoniae* and *Staphylococcus epidermidis*, further they reported the safety of these extracts based on MTT assay and Ame's test. So, it can be stated that the herbal drugs are more efficient and less toxic to various cell lines; hence, they may be explored to replace the less effective antibiotics and/or antibiotics with threatening side effects. Therefore, herbal compounds provide a novel and promising alternative source of antibiotics against microbial agents. The current review highlights the antibacterial activity of the various seed oil extracted from plants against different bacteria.

## TREES AND SEED OIL

Plants mainly propagate through seeds. The seeds may contain nucellus and/or endosperm along with embryo. The nucellar and endosperm tissue contains good amount of stored nutrients, which facilitates the germination of the seed and development of the seedling till the development of first leaf. This reserve food includes carbohydrates, proteins, and lipids. Some tree seeds are rich in oil content.

The lipids are high energy molecules stored by the plants. In perennial trees, the seed oil has been reported from many plants like *Balanites aegyptiaca*, *Azadirachta indica*, *Jatropha curcas*, *Citrus spp.*, and *Paeonia spp* [13 - 17]. The amount of the oil in seeds may vary from 13.74% to 54.37% in plants like *Jatropha curcas* and *Paeonia ostia* [15, 17]. The oil mainly consist of fatty acids, but it also possesses a small quantity of secondary metabolites, which may serve as nutraceuticals and/or drugs to treat various diseases, including bacterial infections.

## SEED OIL CHEMICAL COMPOSITION

Neem seed oil contains the following fatty acids: linoleic acid (34.69%), oleic acid (20.46%), stearic acid (20.42%), palmitic acid (18.66%), arachidic acid (3.59%) behenic acid (0.80%), lignoceric acid (0.55%) and palmitic-oleic acid 0.17% [18]. According to Cesa *et al.* (2019), high pressure liquid chromatography-based chemical analysis of the pure neem oil revealed that it had no phenolic acids [19]. Neem oil had ~24 µg/mL polyphenols, where benzoic acid (12.6µg/mL) and t-cinnamic acid (1.9µg/mL) were found to be the most abundant.

Ahmed *et al.* (2008) studied seed oil composition based on gas chromatography/mass spectrometry (GC/MS) in *Salvadora persica* collected from Gabal Elba, a mountain in East South Egypt [20]. They found that the oil contains mainly heptadecene-8-carbonic acid (~39%), indole (18%), hexadecanoic acid (13%) and octadecanoic acid (8%). Table 1 depicts the detail of seed oils obtained from some trees and their composition.

## Molecular Mechanisms of Antimicrobial Resistance and New Targets to Address Current Drug Resistance

Divyapriya Karthikeyan<sup>1</sup>, Sudhir Kumar Pal<sup>1</sup>, Mukesh Kumar<sup>2</sup>, Kali Kishore Reddy Tetala<sup>1</sup>, Punit Kaur<sup>2</sup> and Sanjit Kumar<sup>1,\*</sup>

<sup>1</sup> Centre for Bio Separation Technology (CBST), Vellore Institute of Technology, Vellore, Tamil Nadu, India

<sup>2</sup> Department of Biophysics, All India Institute of Medical Sciences, New Delhi, India

**Abstract:** Penicillin discovery has put forward great expectations and hope for the treatment of several infectious diseases. Inappropriate and excess use of antibiotics has led to the emergence of antibiotic-resistant (AMR) worldwide, which has become one of the greatest threats to global health. However, in the late 1940s, after approval, mass production (lead to reduced cost) and supply (lead to easy access to all people) led to the emergence of Antimicrobial Resistance (AMR). A similar behavioral pattern ensued as other classes of antibiotics were discovered (through increasing utilization to resistance). Substandard infection control practices in public healthcare settings eased the spread and transmission of resistant organisms and intensified antimicrobials' effect. The healthcare community responded with two major programs – Infection Control in the 1980s and Antimicrobial Stewardship (in the last decade). These programs depend on the end-user; however, while the importance of such global control and prevention programs cannot be disputed, these efforts alone are insufficient against the advent of AMR. Also, drug discovery has suffered from a shortage of exploitable bacterial target sites, leading to the slow evolution of novel potent drugs.

**Keywords:** Antibiotics, Antimicrobials, Antimicrobial resistance, Colistin-resistant, ESKAPE organism, Pan-resistant bacteria, Superbugs.

### INTRODUCTION

A pathogen or an infectious agent is a biological agent that can be catastrophic and sometimes lethal to the host (both unicellular and multicellular organisms). These infectious diseases are caused by varied living agents (pathogens), which can be categorized into 5 groups namely bacteria, viruses, protozoa, fungi, and

\* **Corresponding author Sanjit Kumar:** Centre for Bio Separation Technology (CBST), Vellore Institute of Technology, Vellore, Tamil Nadu, India; E-mail: sanjitkrroy@gmail.com

helminths (worms). Protozoa and worms are usually associated as parasites, whereas bacteria, viruses, and fungi are collectively known as microbes. They can grow in diverse body sections, out of which the major two can be delineated as intracellular and extracellular [1].

To subdue the effects caused by these pathogens (micro-organisms), drugs such as antimicrobials are prescribed. Antimicrobials are the broad classes of substances (natural, semi-synthetic, and synthetic) that act against microorganisms. As a part of antimicrobials, there is also another class of drugs called antibiotics [2], which attributes to the materials generated only by the microbes that work in contradictor to another microbe [3]. Antimicrobials comprise antibiotics, antivirals, antifungals, and antiparasitics. These agents have been in use for so many years to treat infections and wounds [4]. The introduction of these agents, such as sulphonamides (1935), penicillin (in 1941), streptomycin (1943), combination drugs, such as para-aminosalicylic acid (1944) and isoniazid (1952) into clinical practices contributed to a sharp decline in the death of patients affected by diseases such as pneumonia, influenza, and tuberculosis (8.2% per year in the USA) [5, 6].

The beginning of the modernized “antibiotic era” is linked with the names of renowned scientists Paul Ehrlich and Alexander Fleming. The idea by Paul Ehrlich, known as “magic bullet”, selectively exerts its full action only on the infectious microbes and not on the host organism [7, 8]. Since its inception, this became the mainspring of drug discoveries for the last 60 years, where a massive amount of antibiotics have been manufactured and utilized for a wide variety of purposes [9]. Their bombastic production due to technological advances has led to an ever-increasing demand that resulted in non-prescription and off-labeled use. This oversaturation of the globe because of these toxic agents significantly contributed to the selection of resistant strains of microorganisms and their circulation in microbial populations throughout the terrain. This generates an unremitting selection pressure which is not a usual natural process, but a fabricated circumstance overlaid on the environment called Antimicrobial Resistance (AMR) [9]. Ergo, antimicrobial medicines turn out to be feeble and infections become harder or impossible to treat and also increased the probability of disease spread, stern ailment, at last, heading towards the end of life (<https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance>).

### **ANTIQUITY OF ANTIBIOTIC EXPLORATION AND CONCOMITANT PROGRESS OF ANTIBIOTIC RESISTANCE**

Since the introduction of the foremost effective antimicrobial in 1937 (sulphonamides), the maturation of peculiar mechanisms of resistance has haunted

their medicinal application [9]. In the pre-antibiotic era, the presence of antimicrobials (such as artemisinin, a potent anti-malarial drug) [10] in many herbs from Traditional Chinese Medicine (TCM) could be thought of as a means of remedies (used for millennia) [11]. The discovery of such antimicrobial active components during ancient times might have enriched the depository of antimicrobials used by conventional medicine. Simultaneously, selective pressures forced by these antimicrobials through the deep-rooted past of TCM may be one of the components putting up to the aggregation of antibiotic resistance genes (ARGs) in our community [7].

For example, the late 1930s reported the resistance of Sulfonamide and the same mechanism operates even 70 years later also [9]. Even before the entry of penicillin into the market in 1943 as a therapeutic agent, penicillinase, which is of bacterial origin (discovered in 1940) was already identified [12]. With the excessive use of antibiotics, resistant strains (having drug inactivating capability) became widespread, thereafter, artificial studies were ventured to improve the chemical nature of penicillin to block cleavage by penicillinases ( $\beta$ -lactamases).

The streptomycin-resistant mutant strains of *M.tuberculosis* were detected to have risen during the treatment of the disease. In the mid-1950s, in Japan, the unanticipated identification of genetically transferable antibiotic resistance [13] changed the whole picture. Introduction of the concept of skeptical genetics, collections of ARGs could be propagated by bacterial conjugation mostly throughout the community of bacterial pathogens [14].

Over several decades, AMR caused severe infections that developed resistance and are incurable with available and new anti-microbial agents. The techniques like phylogenetic reconstruction help in revealing the history of these resistance genes and recommends the abiding existence of genes favoring resistance to varied antibiotics classes in the environment ahead of antibiotic ages [15]. The usage of molecular biology serves as the means of knowing the provenance and proliferation of drug resistance genes [16, 17].

In recent years, AMR has emerged as one of the key public health issues of the 21<sup>st</sup> century that menaces the effective avoidance and remedy of an ever-expanding range of infections caused by infectious agents that are no longer prone to the customary medicines used to cure them. The complication of AMR, specifically in the case of multi-resistant and pan-resistant bacteria (which are also called “superbugs”), requires urgent attention and solution. Also, the clinical interface of the medical pipeline of new antimicrobials is almost dry. In 2019, the World Health Organization (WHO) addressed the list of priority pathogens and identified 32 antibiotics in clinical development, of which only 6 were thought to



## **Drug Discovery for MDR**

**Jyoti Yadav<sup>1</sup>, Nagendra Singh<sup>2</sup>, Anupam Jyoti<sup>3</sup>, Vijay Kumar Srivastava<sup>1</sup>,  
Vinay Sharma<sup>1</sup> and Sanket Kaushik<sup>1,\*</sup>**

<sup>1</sup> *Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur-303002, India*

<sup>2</sup> *School of Biotechnology, Gautam Buddha University, Greater Noida, India*

<sup>3</sup> *Department of Biotechnology, University Institute of Biotechnology, Chandigarh University, Chandigarh, India*

**Abstract:** Infections caused by MDR (Multi-drug resistant) strains are increasing with time due to the selection pressure posed by the use of antibiotics. The mechanisms that confer antibiotic resistance to bacteria are gene mutation, change in cell envelop, over expression of efflux pumps and biofilm formation. Drug development for MDR has become one of the major challenges globally. MDR infections associated with health care facilities are difficult to treat due to the limited therapeutic approaches or even no treatment options. Therefore, there is an emergency to develop new therapeutic approaches against MDR pathogens. It is possible to identify proteins that are responsible for the survival of pathogenic MDR bacteria for the purpose of drug discovery. Rational-structure based drug design is an inventive process of finding new drug targets, which relies on the knowledge of three-dimensional structure of biological targets. The three-dimension structure is obtained by high throughput techniques such as X-ray diffraction (XRD), Nuclear Magnetic Resonance (NMR) and Cryo-electron microscopy (Cryo- EM). Structure biology plays an important role in the characterization of new therapeutic targets and assessment of drug targets. Computational methods boost drug development and discovery process against MDR pathogens and analyse efficient therapies.

**Keywords:** Antibiotic resistance, Cryo-EM, Drug discovery, Multidrug resistance, NMR, Rational structure based drug design, Structure biology, X-ray diffraction.

### **INTRODUCTION**

Over the past decade, emergence of antimicrobial resistance in pathogenic bacteria has become a major public health concern all over the world. Treatment

---

\* **Corresponding author Sanket Kaushik:** Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur-303002, India; E-mail: sanketkaushik@gmail.com

of several bacterial infections has become increasingly difficult due to the emergence of multidrug resistant strains [1 - 3]. Antibiotics resistance may arise as a result of mutations in the gene, changes in cell envelop, over-expression of efflux pumps, biofilm formation, *etc.* [4, 5]. Multi-drug resistance to different antibiotics develops due to inappropriate use of antibiotics, poor infection prevention and insufficient conditions of sanity [4, 6, 7]. There are several clinical isolates that have developed antibiotic resistant and are more commonly found in hospital environments, such as methicillin resistant *Staphylococcus aureus* (MRSA), vancomycin resistant *Enterococci* (VRE) and the members of the *Enterobacteriaceae* family [8, 9]. Drug development against such multi-drug resistant bacterial strains has become one of the major challenges for medicinal industries [10]. In this regard, it is possible to target essential proteins for the survival of the bacteria for the purpose of drug discovery [11, 12]. Rational structural-based drug design is the process of finding small molecule inhibitors based on the knowledge of three-dimensional structure of biological target proteins [13]. The three-dimensional structures of the targets are obtained by high throughput techniques such as X-ray crystallography, nuclear magnetic resonance (NMR), spectroscopy or cryo-electron microscopy (cryo-EM) [14, 15]. The three-dimensional structure of the target molecule is used to predict candidate drug molecules that selectively and tightly interact with binding sites of the protein or enzyme of the pathogenic microbe. The small molecule inhibitors are chosen as lead molecules against the target [16]. Dorzolamide, saquinavir, zanamivir and imatinib which target carbonic anhydrase, HIV protease, neuraminidase and BCR-ABL respectively, are some of the examples of successful cases of structural-based drug design [16].

## EMERGENCE OF MULTIDRUG RESISTANCE IN BACTERIA

Multi-drug resistance associated with unselective use of prolonged exposure to antibiotics led to excess morbidity, mortality and high cost in clinical settings. It also increased the prevalence of pathogenic multi-drug resistant bacteria globally [17]. It has been noted that over the last few decade plasmid-borne resistance genes and cross resistance are the major factors that facilitates the process of resistance in bacteria [18]. The Infectious Disease Society of America, documented that management of several infectious diseases is extremely challenging such as vancomycin-resistant *Enterococcus faecium*, multi-drug resistant *Acinetobacter baumannii*, methicillin-resistant *Staphylococcus aureus* (MRSA) and *Enterobacteriaceae* [19]. The development of antibiotic resistance occurs mainly due to gene mutation, horizontal gene transfers via conjugation, transformation and recombination events [20]. Broadly there are four mechanisms of multi-drug resistance in bacteria. They are:

- Modification of drug target;
- Drug inactivation;
- Drug target modification; and
- Bypass of target site.

Bacterial resistance leads to difficulty in treatment, causing serious complications in critically ill patients. These resistant bacteria spread not only in healthcare settings but also in communities [21]. Due to the limited options available for the treatment of infections caused by multi-drug resistant pathogens, there is an urgent need to explore new strategies to develop new drug candidates [22].

## ROLE OF STRUCTURAL BIOLOGY IN DRUG DISCOVERY

Structure biology has a huge potential in drug discovery, structural information obtained from native structures of proteins and also their complexes with ligands can be used in designing of the lead compounds [23, 24]. Various industries utilize high-throughput and fragment screening approaches to identify the initial stage of small molecules in the research and development of drug discovery [25]. X-ray crystallography, electron crystallography, neutron crystallography, cryo-electron microscopy, small-angle neutron scattering and electron tomography are commonly used direct imaging techniques in structural biology for drug discovery [26 - 29]. Amongst these techniques, the ones which provide higher resolution in the structural determination of macromolecules complexes are X-ray crystallography, cryo-EM; hence are used more often in structural determination of target enzyme and their complexes with ligands (Table 1) [30].

On the basis of structural knowledge, three dimensional structure of macromolecules provides biological mechanisms and also suggests a new therapeutic mode for rational drug design [31, 32].

**Table 1. Comparison of X-ray crystallography, NMR and Cryo-EM.**

S. No.	X-ray Diffraction (XRD)	Nuclear Magnetic Resonance (NMR)	Cryo-EM
Technique	Involves arrangement of atoms within a crystal.	Involves change in nuclear spin energy in the presence of magnetic field.	Involves analysis of native structure in cryogenic condition which are sensitive towards radiation.
Based	Based on X-ray diffraction pattern.	Based on absorption or electromagnetic radiation in radio frequency range.	Based on native cryogenic condition.

## Recent Developments to Fight Multidrug Resistance (MDR) in Protozoa

Mrinalini Roy<sup>1</sup>, Sanket Kaushik<sup>1</sup>, Anupam Jyoti<sup>2</sup> and Vijay Kumar Srivastava<sup>1,\*</sup>

<sup>1</sup> Amity Institute of Biotechnology, Amity University Rajasthan, Kant Kalwar, NH-11C, Jaipur-Delhi Highway, Jaipur, India

<sup>2</sup> Department of Biotechnology, University Institute of Biotechnology, Chandigarh University, NH-95, Chandigarh-Ludhiana Highway, Mohali, India

**Abstract:** This chapter focuses on the solutions to emerging multidrug resistance in the major parasitic protozoa plaguing the world. These neglected pathogens have seized the developing nations in a vice-like grip and are seeping into the industrialised world with the dramatic increase in global travel. The alarming rise in resistance to most antiparasitic drugs has left even the wealthiest nations vulnerable. Multidrug resistance occurs to give a survival advantage to the parasite; it has been hastened by the uncontrolled use of chemotherapeutics. This chapter categorises the recent developments to overcome the MDR hurdle under different approaches. The synthesis of novel organic compounds and high-throughput screenings of new chemical entities are two major approaches. Protease and topoisomerase inhibitors of parasitic protozoa prove as worthy drug targets. *In-silico* and proteomics-based methods also accelerate drug discovery by creating potential drug libraries specific to tropical protozoa. A cost-effective and rapid method of combating drug resistance is the repurposing of licensed medicines. This approach also accounts for the established safety of drugs and high commercial availability. Molecular advancements have introduced small interfering RNAs (siRNAs) at preclinical levels as therapeutics functioning *via* a unique mechanism. The nanoparticle and cell-penetrating peptides (CPP) based delivery of siRNAs has facilitated a stable and low toxic way to silence genes providing pathogenicity and resistance. This will help in reversing MDR and breathing new life into the existing licensed antiprotozoal chemotherapies.

**Keywords:** Antimicrobial peptides, Antiprotozoal therapeutics, Aystems biology, Drug repurposing, *In-silico*, Multidrug resistance, Protease inhibitors, siRNA, Synthetic organic compounds.

---

\* Corresponding author Vijay Kumar Srivastava: Amity Institute of Biotechnology, Amity University Rajasthan, Kant Kalwar, NH-11C, Jaipur-Delhi Highway, Jaipur, India; E-mail: vksrivastava@jpr.amity.edu

## INTRODUCTION

The blight of protozoan disease is no longer limited to developing and poor nations; it has found a hold in the industrialised world as well due to increased global travel and multidrug resistance. Multidrug resistance (MDR) is defined as the insensitivity of an organism to the administered chemotherapeutics (that have different molecular targets) despite earlier sensitivity to it.

The fitness model of natural evolution promotes MDR. The phenomenon has accelerated in the last two decades with extensive and unnecessary use of chemotherapy. This situation is further complicated by incomplete clearance of pathogens because of viral and lifestyle-induced immune-insufficiency, which creates recalcitrant and recurring infections. The vicious cycle of resistance fuels the further spread of MDR as a consequence of chronic infections and long term hospitalisations that enable hospital-acquired infections to become a hotspot for the exchange of resistance mechanisms between parasites [1].

Pathogenic protozoa have created several MDR adaptations. These include rapid efflux of the drug and the reduction in drug uptake due to modifications in drug transporters. These transporters often hide in plain sight under other simplistic functions. Drug modification, drug degradation and sequestration, genetic mutations and target enzyme modulations, all augment MDR. These mechanisms are illustrated in Fig. (1). Thus, it is essential to formulate nontoxic and cost-effective chemotherapies for managing protozoan infections. Moreover, the new drugs should be mechanistically novel so that existing resistance mechanisms do not render the new drugs ineffective [2, 3].

Scientific and political advancements in developing nations have helped alleviate the obstacles in the drug discovery against parasitic protozoa. A multidisciplinary approach based on structural studies of protozoal proteins, genomic analysis and high-throughput screening of compound libraries has driven this change. In this chapter, you will learn about the recent developments in antiprotozoal therapies to overcome the multidrug resistance to conventional treatments in major pathogenic protozoa.

## NEWLY SYNTHESIZED ORGANIC COMPOUNDS

Researchers have accumulated data about parasitic biochemistry over the last half-century to develop antiprotozoal drugs. They have used this biochemical data to synthesize organic molecules that block the parasitic activities of protozoa [4]. Some of these are first-line drugs, such as metronidazole for gastric protozoa, and pentavalent antimonials for leishmaniasis. However, most conventional drugs are increasingly becoming redundant with the emergence of multidrug resistance [5].

The decades of data from protozoan pathogenicity and metabolomic studies have brought to light, new targets for drug discovery. The researchers have exploited this knowledge to synthesize new organic compounds to launch mechanistically novel drugs in the market. All the new formulations have been compared to standard drugs to check for efficacy and toxicity, before declaring them as potential antiprotozoal therapies [6, 7].




Fig. (1). Schematic diagram of mechanisms of MDR.

Different series of heterocyclic compounds have been studied and their derivatives were synthesized. Among these, a hybrid compound designed by linking molecular scaffolds of pyrazoline and pyrimidine showed excellent activity against *Leishmania donovani* and *Leishmania major* [8]. The Drugs for Neglected Diseases initiative (DNDi) has introduced a highly effective aminopyrazole series for the treatment of visceral and cutaneous leishmaniasis. The aminopyrazole based medicines were not affected by the activity of MDR efflux pumps thus exhibiting a low potential for resistance [9]. The series of 1,3-dipyridylbenzene and terphenyl diamide derivatives revealed good drug candidates against *Trypanosoma brucei rhodesiense* and *Trypanosoma cruzi* strains with  $IC_{50}$  values comparable to the standard drug, melarsoprol. Low  $IC_{50}$  values of  $0.16 \mu\text{M}$  and  $0.10 \mu\text{M}$  were displayed by two imidazolic compounds, against human African trypanosomiasis (HAT) or sleeping sickness [10, 11].

## SUBJECT INDEX

### A

- Absorption, resulting DNA-dye-complex 46
- Acetyl-CoA 101
- Acetyltransferases 101
- Acid(s) 21, 50, 60, 81, 82, 84, 85, 90, 100, 107, 129, 147
  - arachidic 81
  - behenic 81, 84
  - benzoic 81
  - carboxylic 21
  - dicafeoylquinic 147
  - exophyllic 147
  - hexadecanoic 81
  - hexadecatrienoic 84
  - Lauric 82
  - lignoceric 81
  - linoleic 81, 82
  - mycolic 100
  - myristic 82
    - nucleic 21, 50, 60, 107, 129
  - octadecanoic 81
  - oleic 81, 82
  - palmeatelic 82
  - palmitic 81, 82
  - palmitic-oleic 81
  - para-aminosalicylic 90
  - vaccinic 82, 85
- Acinetobacter baumannii* 16, 18, 69, 75, 76
  - resistant 127
- Actinomycetes 112, 145
  - soil-derived 112
- Activity 8, 15, 20, 72, 73, 75, 83, 84, 85, 109, 129, 131, 143, 145, 146, 148
  - antifungal 85
  - bactericidal 75
  - biophysical 131
  - broad-spectrum 20
  - broad-spectrum protease inhibition 145
  - cholesterol-reducing 109
  - low hemolytic 73
- Adenyl transferases 101
- ADME properties 131
- Advanced molecular techniques of siRNA 150
- Advantages of liquid-culture method 36
- Agents 6, 7, 71, 75, 80, 90, 150
  - antibacterial 7, 75
  - antitumor 150
  - infective 6
  - microbial 80
  - toxic 90
- Ame's test 80
- Aminoacyl-tRNAs 109
- Aminoglycoside(s) 15, 16, 70, 98
  - acetyltransferases 16
  - modifying enzymes (AMEs) 15, 16
  - resistance 70, 98
- Aminopenicillin(s) 96, 98, 99
  - and cephalosporin resistance 99
  - resistance 96, 98
- Amphotericin 2
- Amplification 33, 43, 46, 47, 52, 53, 55
  - nucleic acid-based 33
  - reaction 47
- Amplified 52, 53
  - DNA target 52
  - target's melting efficiency 53
- AMPs, mammalian 146
- AMR 37, 95, 104, 105, 106, 109
  - diagnosis in food-originated pathogens 105
  - genes 37
  - mechanisms 109
  - pathogens 95
  - pathways 105
  - sources 104
  - surveillance 104, 105, 106, 109
  - futuristic 105
  - surveillance mechanisms and methods 105
- AMS policies 107
- Analysis 51, 60, 129, 142, 147, 149, 150
  - drug sensitivity 60
  - electrophoretic 51
  - genomic 142
  - molecular docking 149

phenotypic 129  
proteomic 150  
Anti-amoebic activity 147  
Antibacterial 20, 35, 80, 83, 84, 85, 105, 107, 109  
    activities 80, 83, 84, 85, 109  
    susceptibility test (AST) 35, 105, 107  
    therapies 20  
Antibiotic 16, 96, 103, 104  
    consumption 96, 103, 104  
    migration 16  
Antibiotic resistance 2, 6, 7, 9, 10, 14, 17, 90, 91, 97, 103, 104, 105, 111, 126, 127  
    genes (ARGs) 9, 91, 105, 111  
    transferable 91  
Antibiotics 1, 2, 6, 7, 8, 13, 15, 16, 20, 66, 68, 69, 70, 71, 72, 79, 89, 90, 98, 101, 104, 112, 114, 148  
    acyl-depsi-peptide 20  
    aminoglycoside 16  
    aminosidine 148  
    bacterial infection 79  
    bacteriostatic 15  
    biosynthetic 2  
    cycline 71  
    fluoroquinolone 8  
    synthetic 112  
Anti-cancer drug cisplatin forms intra-strand DNA cross-links 21  
Antigiardial and anti-amoebic activity 147  
Anti-inflammatory nanomedicine 149  
Antimicrobial(s) 19, 20, 66, 72, 73, 84, 89, 90, 91, 95, 96, 100, 101, 103, 107, 109, 110, 132, 133, 141, 145, 146, 150  
    drug resistance 101  
    peptides (AMPs) 19, 20, 66, 73, 107, 133, 141, 145, 146, 150  
    resistance mechanisms 100, 132  
    spectrum 72  
    stewardship programs 109  
Antimicrobial activities 22, 67, 79, 80, 83, 84, 101, 132, 133  
    of antibiotics 67, 132  
    of seed oil 83  
Antimicrobial drugs 1, 73

    micro-organisms against 73  
Antineoplastic agents 148  
Antiparasitic activities 146, 147  
Antiprotozoal 141, 142  
    drugs 142  
    therapeutics 141  
    therapies 142  
Antiretroviral therapy 3  
Anti-virulence strategies 74  
Argininosuccinate synthetase 149  
*Artemisia argyi* 147  
Arterolane maleate 144  
*Aspergillus japonicum* 145  
Assay 37, 38, 39, 44, 46, 54, 58, 59  
    hybridization-based 38  
    microarray 39  
    phenotypic 59  
AST of infectious pathogens 106  
ATP 17, 146  
    binding cassette family 17  
    synthesis, reducing 146  
*Azadirachata indica* 85

## B

*Bacillus subtilis* 83, 84  
Bacteria 3, 6, 7, 8, 9, 10, 16, 17, 19, 35, 37, 67, 69, 70, 71, 72, 75, 79, 83, 84, 85, 101, 103, 107, 109, 111, 113, 126, 127, 134  
    antibiotic-resistant 7, 19  
    carbapenem-resistant 69, 70  
    commensal 109  
    drug-resistant 103  
    pathogenic 6, 9, 111, 126, 134  
    producing 72  
Bacterial 15, 20, 21, 71, 74  
    catastrophes 71  
    cell lysis 20  
    functional membrane microdomains 74  
    gene 15  
    membrane bilayer 21  
Bacteriostatic agent 21  
*Balanites aegyptiaca* 81, 82, 84, 85



- Berberis aristata* 80  
Beta 72, 93  
  lactamase-producing 93  
  lactamases 72  
Biofilm inhibitors 21, 133  
Biosynthesis 108, 109  
Block cysteine proteases 145  
Blocking topoisomerase 146  
Bombastic production 90  
Brain injury 21  
Breast cancer 22  
Broad-spectrum 14, 97, 145, 147, 150  
  antibiotics 14, 97, 147, 150  
  antiprotozoals 145  
Bst DNA polymerase 37  
*Burkholderia cenopacia* 71
- C**
- Callophyllum inophyllum* 83  
*Candida albicans* 84  
*Capparis decidua* 82  
Carbapenem-resistant 69, 98, 99  
  Enterobacteriaceae (CRE) 69, 72  
  Klebsiella pneumoniae (CRKP) 69, 98, 99  
Carbazole alkaloids 82, 84  
*Carnobacterium maltaromaticum* 83  
Cell-penetrating peptides (CPPs) 141, 149  
Cephalosporin resistance 99  
Cephalosporins 34, 69, 93, 99, 100  
  third-generation 99  
Chemicals 59, 85  
  natural medicinal 85  
Chemotherapeutic agents 1  
Chemotherapy 18, 92, 142, 145, 147, 151  
  cancer 92  
  safe antiprotozoal 145  
Chloramphenicol acetyl transferases (CATs) 16  
Chloroquine-sensitive Plasmodium genomes 149  
Cholera vaccination 112  
Chronic 92, 99  
  diseases treatment 92  
  liver infections 99  
Chymostatin 145  
Ciprofloxacin 83, 94, 109  
Clomiphene acts 22  
Combination 9, 109, 134, 144, 147, 151  
  of acyldepsipeptide antibiotic and rifampicin 134  
  therapy 9, 109, 144, 147, 151  
Combinatorial therapies 151  
Commercial licensing 147  
Community-acquired pneumococcal infections 95  
Comparison of X-ray crystallography 128  
Computational programmes 149  
Concentrations 15, 53, 54, 56, 101, 146  
  bacterial minimal inhibitory 15  
  bactericidal 101  
  dependent non-receptor 146  
Contamination 22, 23, 46, 51  
  environmental 22, 23  
CRAB infections 71  
CRE 71, 72  
  carbapenemase-producing 72  
  infections 71  
Crude oil 82  
Cryo-electron microscopy 126, 127, 128  
Cryogenic condition 128  
*Cryptococcus* 2, 57  
  *grubii* 57  
  *neoformans* 2  
Cyclic amidines 144  
Cysteine protease (CPs) 144, 145, 146  
Cytomegalovirus 2
- D**
- Dermaseptins 146  
Detecting drug-resistant mutations 60  
Detection 37, 44, 45, 105  
  antibody-based 37  
  genotypic 105  
  of disease-causing pathogens 44  
  of virulent gene and drug-resistant genes 45  
Diacylglycerols 82

- Diarrhoea 43, 84  
Dihydropteroate synthase 95  
Discovery 51, 68, 69, 70, 74, 79, 85, 91, 92, 105, 149, 150  
  antimicrobial 92  
  sequencing-based resistance 105  
Disease(s) 3, 9, 13, 14, 25, 26, 43, 44, 45, 66, 68, 90, 91, 112, 142, 149  
  causing pathogens 44  
  diarrheal 112  
  gastrointestinal 43  
  parasitic 149  
  protozoan 142  
  transmission 25, 26  
DNA 8, 9, 15, 14, 38, 37, 39, 44, 45, 51, 52, 53, 54, 56, 57, 79, 105, 146  
  analysis methods 51  
  bacterial 8  
  duplexes resistance 51  
  fragmented 52  
  genomic 56  
  gyrase genes 15  
  microarrays 38, 39, 105  
  mutations 8  
  polymerases 53, 54  
  repair 146  
  replication 79  
  ribosomal 57  
  topoisomerases 146  
Downregulation, mediated 149  
Doxorubicin hydrochloride 148  
Drug(s) 2, 7, 8, 13, 14, 15, 16, 21, 26, 27, 36, 69, 70, 71, 74, 80, 90, 93, 94, 95, 98, 99, 101, 102, 126, 134, 141, 142, 143, 146, 151  
  aminoglycosides 14  
  antibiotic 15  
  anti-inflammatory 21  
  antileishmanial 146  
  antiparasitic 141  
  anti-virulence 74  
  colistin 101  
  degradation 142  
  delivery vector 146  
  development for MDR 126  
  discovery, tropical disease 151  
  efflux 93, 94, 95  
  for neglected diseases initiative (DNDi) 143, 151  
  glycopeptide 16  
  herbal 80  
  repurposing and repositioning 21  
  susceptibility testing (DST) 36  
Drug resistance 6, 7, 13, 14, 15, 25, 35, 52, 60, 67, 91, 97, 98, 102, 103, 104, 105, 106, 132, 151  
  anti-tuberculosis 35  
  genes 91  
  infections 132  
  mechanisms 60  
  surveillance 106  
Drug target(s) 7, 8, 25, 93, 94, 101, 128, 129, 130, 141, 147  
  modification 7, 94, 101, 128  
  narrow-spectrum 132  
Duplex DNA 52  
Dye(s) 46, 51, 52, 53, 54, 56, 57  
  functions 57  
  fluorescence-based 46  
  fluorescent 51  
  jumping 54  
  saturating DNA-binding 51
- E**
- E. coli* 2, 22, 73, 83, 84, 85, 97, 98, 101, 103  
  antibiotic-resistant 103  
  enteropathogenic 83  
  resistance 84  
Efflux pump inhibitors 134  
Electron 128  
  crystallography 128  
  tomography 128  
Electrophoresis 57, 59  
  agarose gel 57, 59  
Electrostatic interaction 133  
Emergence 3, 6, 7, 13, 18, 33, 68, 70, 72, 89, 127, 133, 142  
  drug-resistant mutant 72

- of multi-drug resistance bacteria 33
  - Endocarditis 9
  - Endocytosis 149
  - Endosperm tissue 81
  - Energy 59, 128
    - nuclear spin 128
  - Entamoeba histolytica* 145, 148
  - Enterococci 17, 18, 34, 127
    - resistant 127
    - vancomycin-resistant 17, 18, 34
  - Enterococcus faecalis* 80
  - Enterococcus faecium* 34, 132, 127
    - vancomycin-resistant 127
  - Environmental 23, 107
    - reservoirs 23
    - stressors 107
  - Enzymatic 8, 25
    - degradation 25
    - reactions 8
  - Enzyme(s) 8, 15, 16, 21, 22, 44, 70, 93, 100, 108, 127, 129, 131, 145, 146, 147
    - aminoglycoside-modifying 70
    - beta-lactamase 8
    - cysteine synthase 147
    - inhibiting thymidylate synthase 21
    - linked immunosorbent assay (ELISA) 44
    - metabolic 129
  - ESKAPE pathogens 132, 133
  - Expression, protozoa gene 148
- F**
- Facial protection 23
  - Factors 6, 9, 55, 56, 57, 101, 146
    - evolutionary conserved natural 146
  - Fatty acids 81, 82, 85, 109
    - biosynthesis 109
    - monounsaturated 85
  - Fecal pollution 103
  - Fluorescence 36, 38, 43, 46, 47, 50, 51, 52, 54, 59
    - emission 54
  - Fluorescence 36, 51
    - light 36
    - resonance energy transfer (FRET) 51
  - Fluoroquinolones 97, 98
    - and aminoglycosides resistance 98
    - resistance 97
  - Folic acid 95, 101
    - preordain 101
  - Food 26, 75, 80, 103, 105, 133, 147
    - and agriculture organization (FAO) 26
    - and drug administration (FDA) 75, 80, 133, 147
    - contaminated 103
    - originated pathogens 105
  - Functional membrane microdomains (FMMs) 74
  - Functions 8, 129, 142, 145, 146
    - antimicrobial drug 8
  - Fungus *Penicillium notatum* 2
- G**
- Gas chromatography 81
  - Gel electrophoresis 59
  - Genes 9, 15, 16, 17, 18, 21, 37, 39, 44, 45, 91, 92, 93, 103, 106
    - chromosomal 34
    - coding 102
    - encoding 14, 15
    - interleukin 59
    - resistant 9, 33, 96
    - sensitive 37
    - silence 141
    - susceptible 33
  - Genetic exchange phenomenon 106
  - Genome 9, 58
    - accessory 16
    - viral 75
  - Genotypic variants leading 58
  - Giardia lamblia* kinase 145
  - Global
    - action plan on antimicrobial resistance 113
    - antimicrobial resistance surveillance system 67
    - crisis 92
    - priority pathogen 71

Glycopeptides 17, 93  
Glycosylation 93  
Glycylcyclines 70  
Growth 2, 20, 35, 83, 84, 111, 134, 149  
  bacterial 20, 83  
  inhibition 84  
  inhibition assays 149  
  inhibitor 84  
  promoters 111  
  reduction 83  
*Gymnema sylvestre* 80

## H

Haemoglobin degradation 144  
Health care systems 3, 27, 33, 110, 114  
  global 33  
  medical 114  
Health care workers 23, 24  
Health professionals 19  
*Helicobacter pylori* 83  
Hepatitis 2, 59  
  chronic 59  
Hepatotoxicity 68  
Herpes virus 84  
Heterocyclic aromatics 150  
Heteroplasmy 58  
High 50, 51, 52, 53, 54, 55, 57, 58, 59, 60,  
  130, 148  
  resolution melting (HRM) 50, 51, 52, 53,  
  54, 55, 57, 58, 59, 60  
  throughput screening 130, 148  
Hip replacements 92  
HIV protease 127  
Homologous proteases 145  
Horseshoe crab hemocytes 73  
Host erythrocytes 145  
Host-parasite interactions 149  
Housekeeping genes 57  
HRM 55, 57, 58, 60  
  assay's efficiency 55  
  efficacy for detecting drug-resistant  
  mutations 60  
  technique 57

  technology 57, 58  
HRM analysis 50, 51, 52, 55, 56, 57, 58, 59  
  of housekeeping genes 57  
Human 2, 59, 143  
  african trypanosomiasis 143  
  genetic variants 59  
  gene variations 59  
  immunodeficiency 2

## I

Illumina sequencing technology 39  
Immunization 9  
Immunoassays 38  
Immunogenicity 150  
Immunological techniques 44  
Immunoreceptor 145  
Inactivation 34  
  enzymatic antimicrobial 34  
Infections 2, 3, 10, 13, 20, 21, 22, 24, 25, 26,  
  59, 66, 67, 84, 90, 91, 95, 99, 111, 112,  
  119, 132, 134, 147  
  bloodstream 99  
  diarrheal 112  
  histolytica 147  
  nosocomial 132  
  respiratory 112  
  skin 2, 84  
  tuberculosis 26  
  urinary 84  
  uropathogenic 99  
  viral 111  
  virus 59  
  yeast 3  
Infectious 43, 44, 59, 67, 89, 96, 104, 106,  
  112, 114, 127, 134  
  diseases 43, 44, 59, 67, 89, 96, 104, 112,  
  114, 127, 134  
  pathogens 106  
Inflammatory conditions 21  
Influenza 2, 3, 90, 111  
Information, genetic 105  
Inhibitors 2, 17, 109, 129, 131, 134, 141, 145,  
  146, 150

- angiotensin-converting enzyme 134
  - nucleotide synthesis 2
  - protease 141, 145
  - protein synthesis 17
  - topoisomerase 141, 145, 146, 150
  - Innate immune response 146
- J**
- Jatropha curcas* 81
- K**
- Kidney disorders 147
  - Klebsiella pneumoniae* 3, 18, 69, 71, 80, 84
    - carbapenem-resistant 69
    - carbapenemase (KPC) 18, 71
- L**
- Lactamases 72
  - Lactobacillus sakei* 83
  - Lateral flow immunoassay 37, 38
  - Leishmania donovani* 143
  - Leishmaniasis 142
  - Lipopeptides 93
  - Lipopolysaccharide 107
  - Liquid culture-based methods 36
  - Listeria monocytogenes* 21, 47
  - Low-density lipoprotein (LDL) 22
- M**
- Macrolides 7, 93, 101, 105
  - Major facilitator superfamily, (MFS) 17
  - Mass 81, 106
    - drug administration (MDA) 106
    - spectrometry 81
  - MDR 13, 19, 23, 24, 33, 35, 37, 38, 126, 148, 149, 150, 151
    - adaptations 142
    - bacteria, pathogenic 126
    - bacterial infections 73
      - contamination 23
      - detection time 35
      - efflux pumps 143
      - genes 37, 38
      - infections 13, 19, 23, 24, 33, 126
      - leishmaniasis 149
      - parasitic protozoa 148, 150
      - protein 38
      - protozoa 150, 151
      - transmission 23
      - tuberculosis 13
      - viruses 13
    - MDR pathogen 24, 73
      - infections 73
      - outbreak 24
    - Mechanisms 6, 8, 9, 10, 13, 15, 17, 22, 67, 69, 72, 75, 84, 105, 126, 127, 142, 143
      - efflux pump 75
      - genetic 105
      - growth-independent 22
    - Medicines, veterinary 103, 110
    - Melting analysis 51
      - fluorescent 51
    - Membrane 8, 16, 129
      - permeability 8
      - proteins 129
      - transporters 16
      - transport proteins 129
    - Metabolism 21, 66, 73
      - iron 21
    - Methicillin-resistant *Staphylococcus aureus* (MRSA) 8, 18, 21, 34, 68, 96, 127
    - Methods 25, 36, 44, 76, 83, 105, 141, 149
      - cell-based screening 149
      - disc diffusion 83
      - genotypic 44
      - phenotypic 25, 36, 105
      - proteomics-based 141
      - target-based screening 149
      - traditional treatment 76
    - Microbes 1, 2, 6, 7, 8, 10, 13, 14, 15, 17, 26, 90, 96, 101, 102
      - drug-resistant 7
      - infectious 90

resistant 2, 14  
Microbial 1, 80, 106  
  diseases 1  
  ecology 106  
  flux pump 80  
  genome sequencing 106  
  infections 1  
Microorganisms 1, 2, 7, 13, 14, 15, 40, 58, 73, 80, 90  
  antibiotic-resistant 80  
  infectious 13  
  resistant 13  
Minimal inhibitory concentrations (MICs) 15, 71, 84  
Minimum inhibitory concentration of seed oil 83  
Molecular 44, 47, 131  
  Beacon (MB) 47  
  docking 131  
  probe-based diagnostics 44  
  technology-based diagnostic methods 47  
Molecules 20, 47, 142  
  organic 142  
  pro-acute MvFR-dependent signalling 20  
  single stranded oligonucleotide 47  
Monocytogenes 21  
*Moringa olifera* 82  
Mosaic proteins production 17  
MTT assay 80  
Multi-locus HRM-based microbial genotyping 58  
*Murraya* 82, 84, 85  
  *koenigi* 84  
  *koenigi* 82, 85  
Mutated genes 15, 96  
  resistant 96  
Mutations 9, 14, 15, 33, 34, 39, 52, 58, 59, 126, 127, 134, 142  
  detection 58  
  gene 126, 127  
  genetic 34, 142  
  pathways 59  
  resistance-inducing 39  
Mycobacterial ATP synthase 93  
*Mycobacterium chelonae* 57

*Mycobacterium tuberculosis* 2, 8, 34  
  for fluoroquinolones 14

## N

Natural 33, 147  
  protozoa inhibitors 147  
  selection theory 33  
Neem oil 81, 83  
*Neisseria gonorrhoeae* 17  
Nephrotoxicity 70  
Neuraminidase 127  
Neutralization 74, 111  
  bacterial toxin 74  
Neutron crystallography 128  
Neutrophils 20  
Non-typhoidal Salmonella infections 96  
Nuclear magnetic resonance (NMR) 126, 127, 128, 129, 135

## P

Parasitic protozoa 141, 142, 146, 150, 151  
  systemic 146  
Paromomycin 2, 148  
Pathogen 43, 44  
  contamination 43  
  detection, amplification-based 44  
Pathogenicity, protozoan 143  
Pathogenic microbes 1, 43, 127  
Pathogenic protozoa 142, 147, 148, 150  
  urinary tract 147  
Pathogens 7, 19, 20, 22, 23, 43, 44, 45, 47, 73, 79, 89, 90, 91, 96, 98, 99, 109, 129, 146  
  bacterial 91  
  diarrhoeal 45  
  drug-resistant 44, 45, 47  
  microbial 73, 79  
  transmissible 22, 23  
Pathway 68, 95, 101, 107, 108, 109, 129, 133, 134, 147  
  bacterial 133  
  biosynthesis 107  
  metabolic 109, 134

- PCR 37, 45, 52, 55  
  based detection 37  
  based system 45  
  reagents and cycling conditions 55  
  real-time 52  
  technique 37
- PCR products 46, 50, 51, 56, 59  
  amplified 50
- Penicillin 8, 17, 34, 69, 90, 91, 93, 94  
  binding proteins (PBPs) 17, 69, 93, 94  
  resistance 17
- Penicillinases 16, 91
- Peptidoglycan 17, 18, 22, 71, 93  
  cell wall synthesis 17  
  synthesis 71
- Periodontitis 9
- Phosphor-transferases 101
- Phytochemicals 79
- Plants oil 79
- Plasmodium falciparum* 148
- Pneumococcal vaccine 111, 112
- Pneumonia 2, 3, 71, 76, 90, 95  
  infections 76  
  ventilator-associated 71
- Polymerase chain reaction (PCR) 35, 37, 39,  
  43, 44, 45, 46, 47, 50, 52, 53, 54, 56, 57
- Polymorphism 50, 59  
  single nucleotide 50
- Process 2, 9, 15, 16, 52, 68, 70, 74, 76, 107,  
  109, 127, 131, 146, 150  
  cellular 109  
  metabolic 14  
  transcription 146  
  translation 15, 16, 70
- Programs 26, 67, 89, 105, 110, 111  
  disease elimination 26  
  universal vaccination 111
- Promastigotes 144
- Properties 8, 20, 59, 84, 131  
  anticancerous 84  
  cytotoxic 20
- Prosopis* 82, 84  
  *cineraria* 82  
  *cineria* 84  
  *juliflora* 82
- Protein-ligand interactions natures 130
- Proteins 8, 13, 21, 126, 127, 128, 129, 130,  
  131, 133, 134, 134, 135, 142  
  protozoal 142  
  virulence-associated 133, 134
- Protozoa 141, 142  
  gastric 142  
  tropical 141
- Pseudallescheria boydii* 2
- Pseudomonas* 18, 69, 76, 80, 83, 84, 132  
  *aeruginosa* 18, 69, 76, 80, 84, 132  
  *fluorescens* 83
- Public-private partnerships (PPPs) 151
- Q**
- Quantitative structure-activity relationship  
  (QSAR) 131
- Quorum 2, 74, 80, 109, 134  
  quench pathogen 74  
  sensing (QS) 2, 74, 80, 109, 134
- R**
- Rational structural-based drug design 127
- Real time PCR 37, 43, 46, 47
- Research 33, 60, 149  
  chemotherapeutic 149  
  epidemiological 60  
  infectious disease 33
- Resistance 2, 3, 6, 7, 14, 15, 16, 17, 20, 59,  
  60, 73, 90, 91, 92, 93, 94, 95, 97, 100,  
  102, 103, 104, 106, 113, 114, 127, 141,  
  142, 151  
  antibacterial 113  
  carbapenem 106  
  defined Amoxicillin-clavulanate 100  
  genes 60, 91, 102, 103, 127  
  intrinsic 7, 14  
  linezolid 15  
  mechanisms 2, 3, 8, 15, 59, 90, 92, 93, 94,  
  95, 103, 114, 142  
  methicillin 15  
  mutations 59

sulfonamide 8  
Respiratory tract diseases 99  
Retinoids 21  
  synthetic 21  
Reverse transcriptase 37  
Rheumatoid arthritis 92  
Rhinosinusitis 9  
Rhodesiense 148  
Rifamycins 7, 15, 94  
RNA interference (RNAI) 148  
RNA Polymerase 15, 94  
  and DNA gyrase genes 15  
RNAi technology 148  
Rotavirus vaccine 112

## S

*Salmonella enterica* 84  
Sanitation interventions 112  
Screening 34, 38, 52, 57, 59, 108, 149, 150  
  computer-aided 150  
  whole-library 149  
Seed oil and antibacterial activities 83  
*Shigella flexneri* 80  
Single nucleotide polymorphism (SNPs) 50,  
  57, 59  
Skin, amphibian 146  
Solid-culture Methods 36  
*Staphylococcus* 17, 34, 80  
  *epidermidis* 80  
  *pneumoniae* 17, 34  
*Staphylococcus aureus* 8, 9, 15, 18, 34, 83, 84,  
  127, 132  
  methicillin-resistant 18, 34, 127  
  resistant 127  
*Streptomyces cattleya* 69  
Susceptibility 22, 52, 105  
  age-old antimicrobial 105  
  restoring MRSA 22  
  therapeutic 52  
Synthesis 70, 145, 150  
  chemical 145  
  protozoa vaccine 150  
  target protein 70

Synthetic peptidomimetics 146  
Systems, immune 73, 75, 134

## T

Target 15, 34, 37, 93, 126, 127, 128, 131  
  biological 126  
  carbonic anhydrase 127  
  drug-resistance genes 37  
  enzyme 128  
  interaction 131  
  protein 15, 34  
  resistance pathogens 93  
Target DNA 44, 46, 47  
  quantification of 44, 46  
Techniques 22, 35, 36, 37, 39, 45, 59, 91, 128,  
  129, 131, 135  
  ligand screening 131  
Technology, cost-effective SNP genotyping  
  57  
Tetranortiri terpenoid 85  
Therapeutic 18, 66, 73, 91  
  agents 66, 73, 91  
  procedures 18  
Therapy 20, 59, 80, 110, 146, 151  
  anticancer 146  
  broad-spectrum empirical 80  
  pathogen-directed 110  
Throat, sore 102  
Tocopherole glucosinolate 85  
Tolerance 67, 132  
*Toxoplasma gondii* 2  
Traditional 66, 67, 68, 72, 79, 84, 85, 91  
  Chinese medicine (TCM) 91  
  medicines 66, 68, 72, 84, 85  
  methods 67, 79  
Transduction 9, 10, 15, 109  
  bacterial two-component signal 109  
Transfer 9, 10  
  genes 9  
  of antibiotic resistance 10  
Transformation 9, 10, 15, 17, 34, 127, 130  
  natural 17  
  process 9



Translational machinery 79, 109  
Transmembrane kinases 149  
Transmission of resistance 104  
Transposons 16  
Treatment 13, 18, 19, 20, 21, 25, 26, 27, 33,  
59, 75, 92, 128, 132, 134  
anti-virulence 20  
pathogenesis 26  
*Trichomonas vaginalis* 2, 145  
Trichomoniasis, resistant 145  
*Trichosporon beigeli* 2  
*Trypanosoma brucei* 148  
Trypanosomatids 147  
*Tubercle bacilli* 14  
Tuberculosis 3, 8, 26, 36, 70, 90, 96  
multidrug-resistant 96  
Typhoid fever 76

## U

UDP-diacetylglucosamine 108  
pyrophosphohydrolase 108

## V

Vaccination 111, 112  
applying Influenza 111  
VAMPPr variant detection method 106  
Vancomycin 7, 9, 14, 16, 17, 18, 21, 34, 70,  
93, 127  
Vancomycin 17, 18, 34, 127  
resistance in enterococci 17  
resistant enterococci (VRE) 17, 18, 34, 127  
Ventilator-associated pneumonia (VAP) 71,  
72  
*Vibrio* 84,  
*cholera* 84  
*ogava* 84  
Virulent gene 45  
Virus(s) 1, 2, 3, 9, 34, 75, 89, 90, 134  
lytic 134  
natural bacterial 20  
transduction process 9

## W

WHO guidelines 22  
Whole genome sequencing (WGS) 35, 39  
World health organization (WHO) 2, 3, 24,  
25, 26, 27, 33, 34, 35, 36, 67, 68, 71, 91,  
98  
Wound infection 102

## X

X-ray 126, 127, 128, 129, 131, 135  
crystallography 127, 128, 131, 135  
diffraction (XRD) 126, 128, 129



**Sanket Kaushik**

---

Dr Sanket Kaushik is an A/Professor at the Amity Institute of Biotechnology, Amity University, Rajasthan. After obtaining his master's degree in 2008 from the University of Rajasthan, he received his Ph.D. degree in Biophysics from the Department of Biophysics, All India Institute of medical sciences, New Delhi. Currently, he is working on structural studies of protein drug targets from Multi Drug Resistant bacteria *Enterococcus faecalis* in its native state and complex with known and designed inhibitors. *Enterococcus faecalis* is a Gram positive multidrug resistant bacterium that is a common cause of hospital-born infections. His major attention lies in investigating the details of host-pathogen interface through structural biology tools for understanding the mechanism of biofilm formation leading to the development of multi drug resistance. He has authored more than 50 research papers and many book chapters. Dr Kaushik has received research grant from several funding agencies in India. He has also worked as a member of the Biotech research society of India and as one of the founder members in Bio footprints. Dr. Kaushik is also working as an academic editor and a reviewer in many scientific journals of international repute.



**Nagendra Singh**

---

Dr. Nagendra Singh is a professor of Biotechnology at Gautam Buddha University, Greater Noida, India. He obtained his postgraduate degree in Biochemistry from Jamia Hamdard University, New Delhi. He received his Ph.D. in the field of Structure Biology from All India Institute of Medical Sciences (AIIMS), New Delhi in 2004 from the Department of Biophysics. He has submitted over 200 PDB entries to the Protein Data Bank. After a few stints as a postdoctoral fellow/senior research officer/senior research associate at AIIMS, New Delhi, He was appointed at the School of Biotechnology, GBU in 2010. Dr. Singh has published over 70 peer-reviewed international research articles with a current H-index of 24. His current research interests include studies on RNA editing enzymes, antimicrobial proteins and drug design using structural biology approaches. Dr. Singh has been awarded by the National Academy of Sciences of India (NASI, Allahabad) young scientist award, Venus International Foundation Young Scientist Award, DST young scientist Award, Meeting of Noble Laureates and Students award in the field of medicine, Lindau, Germany by Govt of India and Best Ph.D. thesis award by AIIMS, New Delhi. Dr. Singh has also been awarded many travel awards from CCP4 UK, Indian National Science Academy, (INSA), Department of S&T, Department of Biotechnology and Council of Scientific and Industrial Research, etc. Dr. Singh is a member of the Indian Biophysical Society and Indian Crystallographic Association. He has been invited to many international and national conferences to present his research work.